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SY01-1
LIVER TRANSPLANTATION FOR
ADVANCED HCC: HOW FAR CAN WE
GO?
Kyung-Suk Suh
Seoul National University Hospital, Korea
Recurrence of transplant recipients with far advanced
hepatocellular carcinoma (HCC) including macrovascu-
lar invasion or huge HCC or numerous HCC is com-
mon and macrovascular invasion is considered as a
contraindication of liver transplantation. A living
donor is uniquely matched to a certain recipient and
this special relationship between a donor and recipient
can provide a patient with the opportunity to undergo
liver transplantation even in suboptimal patients with
advanced HCC. However, a high probability of tumor
recurrence should evoke ethical issues concerning risk
to the living donor. There are no accepted criteria for
patients with tumors that lie outside the conventional
criteria (e.g. Milan criteria). To expand the Milan crite-
ria, prognostic factors other than size and number of
tumor may be necessary. Between November 1997 and
December 2005, 104 cases of liver transplantation for
patients with HCC were performed at our center.
Twenty-four patients did not meet the Milan criteria
preoperatively. Among these 24 patients, 19 had no
major vascular invasion at the time of surgery. We ana-
lyzed the survival and prognostic factors of these 19
patients. The mean follow-up period was 33 months
(range 6–89). Three-year survival rate in 19 patients
was 67.4%. Three-year survival rates were significantly
higher when preoperative alpha-fetoprotein was less
than 400 ng/ml (86.2 vs. 0%, P < 0.001) when Edmon-
son-Steiner’s histological grade 1 or 2 (100 vs. 40%,
P = 0.036) and when microvascular invasion was absent
(78.6 vs. 30%, P = 0.039). Only AFP was a preopera-
tive factor. Positron emission tomography using F-18
fluoro-2-deoxy-d-glucose (18F-FDG-PET) imaging is
now well established as a noninvasive diagnostic tool
for the detection of a variety of malignant tumors.
However, in the case of HCC, several investigators
have reported controversial conclusions and an inade-
quate sensitivity for PET (50%–55%). Nevertheless, a
high positive rate of FDG accumulation has been
reported in patients with high-grade HCC and in those
with markedly elevated alpha fetoprotein (AFP) levels.
When we analyzed the association between tumor fac-
tors and PET (+) (greater PET lesion uptake) in liver,
preoperative AFP level and vascular invasion were
found to be significantly associated with PET (+) (P =
0.003 and P < 0.001, respectively). The 2-yr recurrence-
free survival rate (2-yr RFSR) of PET (-) patients was
significantly higher than that of PET (+) patients
(85.1% vs 46.1%) (P = 0.0005). PET imaging could be
a good preoperative tool for estimating the post-LT
risk of tumor recurrence, because histological grade
and vascular invasion cannot be determined preopera-
tively. The retrospective data of 178 consecutive HCC
patients who underwent LDLT from January 2003 to
December 2009 in Seoul National University Hospital
were collected. We analyzed 113 patiens who were eval-
uated all 3 tests including 18F-FDG PET positivity,
serum AFP level and serum PIVKA II level preopera-
tively. Multivariate analysis showed that serum AFP
level, serum PIVKA II level and 18F-FDG PET posi-
tivity were statistically significant variables. HCC of all
3 patients with high risk of 3 biological factors and
within Milan criteria were recurred. However, HCC of
only 1 patient among the 9 patients beyond Milan cri-
teria and with low risk of biological factors (AFP<100
ng/mL, PIVKA II<100 mAU/mL, PET negative) were
recurred. We did another study about far advanced
HCC. 22 transplant recipients with HCC larger than
10 cm or more than 10 numbers or with macrovascular
invasion preoperatively from January 2003 to October
2010 were included. 1 year disease free survival (DFS)
and 2 year DFS were 40.9% and 23.9%, respectively.
1 year survival rates (SR) and 2 year SR were 71.6%
and 59.7%, respectively. 6 patients were without tumor
recurrence and the median survival duration was 25.4
(13–85) months and the median survival duration of 16
patients with tumor recurrence was 12.37(3–40)
months. There were no statistical differences of DFS
and SR according to macrovascular invasion (MVi)
and 2 year SR were 68.2%(no MVi) and 50.9% (MVi).
There were no significant different outcomes according
to treatment modality. However, there was significant
different 2 yr DFS according to serum alpha-fetopro-
tein level, 54.5% (AFP<200 ng/mL) and 0.00%
(AFP>200 ng/mL) after LDLT (P = 0.023). Tumor
biological markers have the possibility to overcome the
limitation of the Milan criteria. Preoperative serum
AFP level, PIVKA II level and 18F-FDG PET positiv-
ity of the tumor predict the tumor recurrence better
than Milan criteria in living donor liver transplantation
for the patients with HCC. The patients with far
advanced HCC have usually poor prognosis. However,
the patients even with far advanced HCC can have bet-
ter outcome after living donor liver transplantation if
we select the candidates carefully by better selection cri-
teria such as alpha-fetoprotein.
SY01-3
HOW TO REDUCE HCC RECURRENCE
AFTER LIVER TRANSPLANTATION?
Chih-Che Lin
Kaohsing Chang Gung Memorial Hospital, Taiwan
Liver transplantation has been a standard and the most
effective treatment for end stage liver disease. In terms
of treating hepatocellular carcinoma (HCC), liver trans-
plantation provided 75% of 5-year survival rate in case
of tumors within UCSF criteria. For tumors beyond
UCSF criteria, many centers performed liver transplan-
tation with extended criteria, the recurrent rate, as pre-
dicted, would become higher with the extent of criteria.
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Pre-transplant downstaging procedure for HCC to meet
UCSF criteria (TACE) is an alternative approach for
patients with HCC beyond criteria. The tumors beyond
UCSF criteria were pre-treated with local regional abla-
tion, transarterial embolization (TAE) or resection,
liver transplantation wound be performed until the
tumors were effective response to therapy and shrank
to within criteria. Sequential liver transplantation
defined as performing transplantation　after curative
resection for HCC without recurrence was advised for
the patients with resected HCC revealing high risks of
recurrence such as large tumor size and multinodularity
without major vascular invasion. Salvage live donor
liver transplantation carried higher surgical morbidity
than primary live donor liver transplantation (5.4% vs
0.8%, P = 0.016). The recurrent rate (7.1% vs 8.9%)
and disease-free survival were similar between salvage
and primary liver transplantation. Pre-transplant AFP
(>200) (OR: 4.9 CI:1.1-6.0) and vascular invasion
(OR:2.6 CI: 1.2-6.4) were the most predictable factors
for HCC recurrence. The 1-year, 3-year, and 5-year
survivals of recipients within Milan criteria were 98%,
96%, and 90%, respectively. The overall 1- and 5-year
survival rates of all HCC patients were 93.2% and
80.5%. There were no differences of patient survivals
and recurrence rate between downstaged and non-
downstaged patients. There were no mortality and
HCC recurrence in 14 patients who underwent sequen-
tial liver transplantation. Optimal downstaging strategy
and patient selection reduce HCC recurrence after liver
transplantation. The policy may provide cost- effective
indication of liver transplantation for HCC.
SY02-2
PREOPERATIVE BILIARY DRAINAGE:
ENDOSCOPIC VS. PERCUTANEOUS
APPROACH
Thomas Van Gulik
Academic Medical Center, Netherlands
Introduction: The indication for preoperative biliary
drainage (PBD) has long been an area of contro-
versy. In patients with jaundice due to distal cholan-
giocarcinoma in whom a pancreatoduodenectomy is
indicated, a recent RCT showed a higher rate of seri-
ous complications in the drainage group leading to
the conclusion that PBD should not be routinely per-
formed. However, this is not the case for the more
proximal cholangiocarcinomas, i.e. HCCA. An impor-
tant difference between distal tumours as compared
with hilar tumours lies in the need for an (extended)
liver resection in most patients with HCCA. Liver
resections in jaundiced patients are associated with
significantly increased rates of mortality and morbid-
ity, resulting mainly from the development of postop-
erative complications such as sepsis, bleeding, and
most importantly, liver failure. Another important
difference lies in the complexity of the procedure
required to relieve jaundice in HCCA, which usually
involves several segmental bile ducts. Therefore, PBD
is recommended in patients with HCCA requiring
major liver resection.
Method: There are several methods to achieve PBD;
endoscopic biliary drainge (ERCP), percutaneous tran-
shepatic biliary drainage (PTBD) and endoscopic na-
sobiliary drainage (ENBD). The preferred technique of
biliary drainage prior to surgery for a proximal bile
duct tumor depends mainly on local expertise.
Results: ERCP usually does not offer the possibility to
perform selective biliary drainage, and typically, only
part of the biliary system can be drained adequately.
ERCP is therefore not feasible, or eventually not suc-
cessful in a substantial part of patients with HCCA,
requiring conversion of ERCP to PTBD or ENBD.
Complications of ERCP that have been reported
include: cholangitis, acute cholecystitis, pancreatitis,
duodenal perforation, postpapillotomy bleeding, biliary
perforation and tube occlusion requiring re-interven-
tion.
PTBD has a distinct advantage over ERCP in that with
ultrasound guidance one or more appropriate segments
for drainage can be chosen. The extent of tumor infil-
tration proximal to the obstruction can usually be pre-
cisely determined by PTCD.
Several specific complications after PTCD have been
reported, including portal vein injury and thrombosis,
cholecystitis, biliovenous fistula, biloma and hemobilia.
An additional advantage of the percutaneous route of
biliary drainage is that the biliary tubes are an aid to
locate the bile ducts proximal of the tumor in the liver
parenchyma and that after the resection has taken
place, the tubes can be used as transanastomotic drains
to facilitate healing of the hepaticojejunostomies.
Regarding ENBD, less information has been reported
in literature. The availability of an external drain in
ENBD allows contrast cholangiography at any time via
the nasobiliary tube. ENBD also permits evaluation of
the volume and color of biliary secretions. In addition
to the burden of bile suppletion either via the oral
route or via an additional gastro-duodenal tube,
patients may experience severe discomfort of the
ENBD tube passing through the nose.
Conclusion: The three drainage techniques, i.e. ERCP,
ENBD and PTCD, all have their own pros, cons, and
indications. These techniques are often used in combi-
nation with each other. Studies comparing PBD tech-
niques in resectable HCCA are scarce and report
conflicting results, precluding solid advice. Thus, until a
well designed RCT proves otherwise, the preferred
technique of biliary drainage prior to surgery for
HCCA mainly depends on individual anatomy and on
institutional expertise.
SY02-3
SURGICAL RESECTION FOR
PERIHILAR CHOLANGIOCARCINOMA
Masato Nagino
Nagoya University Graduate School of Medicine, Japan
Perihilar cholangiocarcinoma still remains the most
difficult challenge for hepatobiliary surgeons. Achieving
negative surgical margins often ends in failure as the
bile duct bifurcation is very close to the vascular inflow
to the liver. Surgical indication (= resectability),
especially combined vascular resection, is still largely
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different from institute to institute. The aim of this
study was to outline our experience of surgical treat-
ment of perihilar cholangiocarcinoma. Between April
1977 and December 2010, a total of 754 consecutive
patients with perihilar cholangiocarcinoma were trea-
ted, of whom 574 (76.1%) underwent resection. The
medical records of these resected patients were retro-
spectively reviewed. Only 19 (3%) patients underwent
bile duct resection, and the remaining 555 underwent
hepatectomy. Types of hepatectomy performed were:
resection of S1 + 4-8 in 43 patients; resection of
S1 + 5-8 in 177; resection of S1-5 + 8 in 110; resection
of S1-4 in 187; and other segmentectomies in 38. Com-
bined pancreatoduodenectomy was carried out in 74
patients (13%), portal vein resection and reconstruction
in 206 (36%), and hepatic artery resection and recon-
struction in 76 (13%). R0 resection was achieved in 439
(77%) patients. Mean operative time was
668  134 minutes, and intraoperative blood loss was
2491  2156 mL. Of the 574 resected patients, 27 died
of postoperative complication. Thus, overall mortality
was 4.7%; it decreased recently, being only 2.1% (8/
386) after 2001. Overall 3- and 5-year survival rates
(including all deaths) were 44.6% and 33.1%. Survival
for the 386 patients after 2001 improved significantly
compared to that for the 188 patients before 2000
(49.3% at 3 year and 40.0% at 5-year vs. 36.2 at 3-year
and 23.1 at 5-year, P < 0.0001). Hepatectomy for peri-
hilar cholangiocarcinoma is performed safely with
acceptable mortality. Aggressive resectional approach
can offer a better chance of long-term survival in
selected patients.
SY03-1
HEPATIC RESECTION FOR ADVANCED
HEPATOCELLULAR CARCINOMA
WITH INFERIOR VENA CAVA TUMOR
THROMBUS
Hiroaki Nagano
Osaka University Hospital, Japan
Involvement of the inferior vena cava (IVC) has been
considered as contraindication for surgical treatment of
hepatocellular carcinoma (HCC), because of poor prog-
nosis and high surgical risk. The development of inno-
vative surgical techniques has made a curative surgical
approach to tumors involving both liver and IVC pos-
sible.
In this symposium, we will present about the operative
procedure and the outcome of the liver resection for
far advanced HCC with IVC tumor thrombus in our
department. The tumor thrombus is a state in which
the floating blood vessel in general, not invading the
HV and/or IVC. Therefore, no vascular resection neces-
sarily, removal of tumor thrombus from IVC, should
be applied. As a method, it is important to expose suf-
ficiently the blood vessel wall for handling and dissect-
ing IVC. In surgery for patients with tumor thrombus
in IVC, the reconstruction is not needed in almost all
cases after removal of thrombus. The use of artificial
heart-lung is decided after confirming the atrial side tip
of the tumor thrombus by trans-esophageal echo dur-
ing the surgery. Of the 931 cases HCC who underwent
hepatic resection, 37 cases (4.0%) have (Vv1-3) patients
with hepatic vein (HV) and/or IVC, including 21 cases
with IVC tumor thrombus (Vv3) (2.3%), in our depart-
ment. Concerning the outcome of the 21 patients with
IVC tumor thrombus, it was possible to perform the
hepatic resection and the removal of tumor thrombus
safely in all cases with no surgery-related death; no use
of artificial cardiopulmonary bypass in 20 cases but
one exception with self-pericardium in IVC reconstruc-
tion. The median operative time was 490 minutes
(230-950 minutes); the median blood loss was 3950 ml
(530-46000 ml). The surgical outcome of these cases in
1- and 2- year survival rates were 56.7% and 31.5%,
respectively. Surgical resection for the advanced HCC
with IVC tumor thrombus is the possible procedure
with considerable oncological results, being careful sep-
aration of the liver and IVC important.
SY03-2
HEPATECTOMY AND BACK FLOW
TUMOR THROMBECTOMY FOR
ADVANCED HEPATOCELLULAR
CARCINOMA WITH EXTENSIVE
PORTAL VEIN TUMOR THROMBUS IN
COMBINATION OF PERCUTANEOUS
ISOLATED HEPATIC PERFUSION
(PIHP)
Yonson Ku
Kobe University Graduate School of Medicine, Japan
Hepatectomy remains the best therapeutic option for
patients with hepatocellular carcinoma (HCC). Even
for those with portal vein tumor thrombus (PVTT),
hepatectomy and tumor thrombectomy should be con-
sidered to prevent a life-threatening sequence of events
such as variceal hemorrhage and liver failure. In gen-
eral, PVTT within the ipsilateral portal branch can be
resected together with primary tumors by en-bloc fash-
ion at a time of a right or left hemihepatectomy. Previ-
ous studies have reported thrombectomy techniques for
PVTT extending into the main portal vein or contralat-
eral first-order portal branch. Unfortunately, however,
a number of patients with PVTT are complicated with
a more deeply sitting one at the time of diagnosis. To
improve the prognosis of such patients with extensive
PVTT that extends contralateral second- to third-order
braches, development of a simple and effective thromb-
ectomy technique and a strategy of treating dissemi-
nated intrahepatic metastatic tumors are imperative.
The aims of the present study were to describe a novel
tumor thrombectomy technique and to report the long-
term outcomes with reductive hepatectomy and tumor
thrombectomy in combination of percutaneous isolated
hepatic perfusion for advanced HCC with extensive
PVTT. Macroscopic classification of PVTT: We classi-
fied PVTT into two types based on the macroscopic
forms of PVTT. One is the floating type and the other
the expansive type. Both types could exist in the same
patient. The diameter of the portal vein, in which float-
ing PVTT exists, is smaller than the original caliber of
the portal vein and PVTT is floating in portal blood
flow. On the other hand, the expansive PVTT is fre-
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quently extending into the tiny branches of the portal
vein, and the diameter of the portal vein, in which the
expansive PVTT occupies, frequently become bigger
than the original caliber of the portal vein due to its
expansive growth. Back flow tumor thrombectomy
(BFT): BFT technique is applied for PVTT extending
into contralateral portal branches. It consists of the fol-
lowing 4 elements: Portal vein trunk is clamped above
the pancreas. Hepatic venous blood back flow towards
the portal vein is maintained during thrombectomy
procedure. After a transverse venotomy, PVTT is
peeled off, crushed, and extracted by a suction device
with the aid of forceps and scissors. Portal blood back
flow facilitates effective extraction of both micro-and
macroscopic cancer nests. This floating type of PVTT
can be easily extracted by the BFT technique, while
thromboendo venectomy, mechanical crushing and
extraction of PVTT are required to remove the expan-
sive type. Sequential PIHP after reductive hepatectomy
and tumor thrombectomy: The detailed procedure of
PIHP was described elsewhere. PIHP was performed
under general anesthesia. In brief, on the day of treat-
ment, patients underwent hepatic arteriography (HAG)
to place a hepatic arterial infusion (HAI) catheter by
Seldinger’s technique. Patients received a 20- to 30-min
continuous HAI of cytotoxic agents after which extra-
corporeal drug filtration was maintained for >10 min.
The first PIHP was performed 1–3 months after reduc-
tive hepatectomy, and the interval between PIHP ses-
sions ranged from 1 to 5 months. Before March 2002,
patients received single-agent doxorubicin 100–120 mg/
m2, and from April 2002 onward patients received
doxorubicin 100–120 mg/m2 plus mitomycin C
20–40 mg/m2. The doxorubicin dose was reduced for
repeat PIHP according to pretreatment leukocyte
counts. Operative procedures: BFT technique is pre-
sented by movies in a patient with PVTT extending
into the contralateral (left) second-portal branch. BFT
technique was applied in combination of right hepatec-
tomy for the patient. After dissecting and taping the
left portal vein, the portal trunk is fully exposed up to
its bifurcation. First, the right hepatic artery is ligated
and divided at the right side of the common bile duct.
The root of the right portal vein is opened with a trans-
verse venotomy at an appropriate site near the bifurca-
tion and tumor thrombus in the portal trunk and left
portal vein is peeled off, crushed, and extracted by
means of forceps and scissors with suction devices. Of
an important note, the vascular clamp at the left portal
branch should be avoided for PVTT extending distally
to the contralateral second portal branch. Vascular
clamping on the PVTT containing vessel carries a risk
of remnant liver infarction due to embolization with
fragmented tumor thrombus. Prognostic outcomes:
Until the end of 2012, 43 patients with multiple bilobar
HCC and PVTT into the contralateral first- to third-
order portal branch underwent major hepatectomy with
tumor thrombectomy. BFT technique was used in 22 of
43 patients with extensive PVTT. Of 22 patients with
BFT, 4 had PVTT extending into the contralateral
first-order, 14 into second-order, and the remaining 4
into third-order portal branch. Patency rates of portal
vein at thrombectomy site of 22 patients with BFT
were 90% and 86% at 3 and 6 postoperative months,
respectively. The median OS of all 22 patients with
BFT was 17 months and the 1- and 3-year OS rates
were 69.2% and 23.1%, respectively, while those of 18
patients with PVTT at the contralateral second- or
third-order portal branch were 66.7% and 22.3%,
respectively, with the median OS of 14 months. Tumor
thrombectomy by BFT achieves a high rate of portal
vein patency 6 months after hepatectomy and expands
a therapeutic time window for patients with multiple
bilobar HCC and deeply sitting PVTT for whom either
sorafenib or best supportive care is currently recom-
mended.
SY03-3
HCC WITH BILE DUCT INVASION
Hee Jung Wang
Ajou University Hospital, Korea
Hepatocellular carcinoma(HCC) patients with gross
bile duct(BD) invasion are thought to have poorer
prognosis than other HCC patients, probably because
many do not receive effective treatment. Surgical resec-
tion is the only option for curative treatment of these
patients. However, there are still some debates such as
1) What is adequate extent of liver resection for cura-
tive treatment? 2) Is extrahepatic bile duct resection
mandatory for cure? 3) If primary tumor is fulfilling
Milan criteria, can liver transplantation be considered
for HCC with BDTT? I will talk about these issues in
this symposium through my personal experience and a
Korean multicenter study. From 1994 to 2007, 452
consecutive HCC patients underwent hepatic resection
and were retrospectively analyzed at my institution.
Twenty (4.2%) HCC patients were with gross BDTT
(B3 or B4). The first 3 patients underwent minor hepa-
tic resection with only removal of BDTT for first
2 years. Results showed that HCC recurred in the int-
rahepatic bile duct in all patients within 4 months, and
died within 10 months after surgery. From these early
experiences, I thought that patients with icteric HCC
should receive at least hemihepatectomy. Thereafter,
the remaining 15 patients (excluding 2 case with gross
portal vein tumor thrombi) all underwent ipsilateral
hemihepatectomy. Their 1-, 3-, 5-, and 10-year survival
rate were 79.0%, 51.5%, 40.4% and 27.9%, respec-
tively. They were divided into two groups: cases under-
went hemihepatectomy with extrahepatic bile duct
resection (Group 1: n = 9) and with only removal of
BDTT (Group 2: n = 6). The 1-, 3-, and 5-year survival
rates of Group 1 were 87.5%, 73.2%, and 56.5%, and
those of Group 2 were 43.2%, 43.2%, and 0%, respec-
tively. (P < 0.05) Therefore, I personally suggest that
the adequate surgical procedure for icteric HCC
patients should comprise of ipsilateral hemihepatecto-
my with caudate lobectomy and extrahepatic bile duct
resection. According to the recent study for 73 patients
from four Korean institutions, their 1-, 3-, 5-, and 10-
year survival rate were 76.5%, 41.4%, 32.0% and
17.0%, respectively. Results of univariate survival
analysis showed that maximal tumor size, bile duct
resection, and s urgical curability were significant risk
factor for recurrence. Multivariate analysis did not
reveal any independent risk factors. I propose a global
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study for debates in HCC with gross BD invasion
because of its rare incidence. It is fortunate for Korea-
Japan liver surgeons to start a collaboration project for
this subject from this year.
SY03-4
HEPATOCELLULAR CARCINOMA AT
THE CAUDATE LOBE
Jiahong Dong
Chinese PLA General Hospital, China
Treatment for hepatocellular carcinoma(HCC) originat-
ing from the caudate lobe (CL) is difficult,because of
its deep dorsal location and adjacency to the porta he-
patis and IVC. The aim of the present study was to
analyze the effect of different treatments for HCC at
the CL. A literature review was performed based on a
Pubmed search to identify articles on treatment for
HCC at the CL published from 1990 to 2013. This arti-
cle describes different types of caudate lobectomy in
detail (isolated resection and extended resection, partial
or complete resection), three approaches to the CL (the
right/left-sided and anterior transhepatic approach), as
well as non-surgical treatments including radiofrequen-
cy ablation (RFA), transcatheter arterial chemoemboli-
zation (TACE), percutaneous ethanol injection (PEI)
etc. The results of 1,015 patients with HCC at the CL
were analyzed in this review. Caudate lobectomy were
performed in 531 (52.3%), TACE in 304(30.0%), RFA
in 130(12.8%), PEI in 19(1.9%), other treatments in 31
(3.1%) cases. The effect of caudate lobectomy for
patients with HCC at the CL was affirmative, with the
postoperative overall 5-year survival rate from 25.9%
to 76%. Access to and resection of the CL were deter-
mined on the basis of tumor location, vascular involve-
ment and liver functional reserve. There was no
significant difference in postoperative survival rate
among different types of caudate lobectomy. Tumor
location, liver cirrhosis and surgical margin were signif-
icant independent prognostic factors for postoperative
overall survival. HCC at the CL have a prognosis com-
parable to that of patients with HCC in other parts of
the liver. Effect of non-surgical treatments was uncer-
tain and controversial. Surgical resection, although
technically demanding, is the first-line treatment for
HCC at the CL with an affirmative and controllable
effect. Non-surgical treatments may act as an adjuvant
therapy modality, due to its high recurrence rate and
uncertain effect. Prospective randomized controlled
multicenter trials are required for further appraisal of
treatment for HCC at the CL.
SY03-5
HUGE HCC
Sasan Roayaie
North Shore- LIJ health system, U.S.A.
Despite an increased awareness of the need for screen-
ing for HCC in patients wuth liver disease, many
patients still present only after the development of
symptoms. These large tumors present a challenge to
the clinician. Often, these large tumors are accompa-
nied by gross vascular invasion. The litterature was
reviewed to determine the natural history of large
(>10 cm) HCC. The outcome after treatment with sur-
gery, ablation, embolization, and systemic therapies as
well as a combination of these modalities was extracted
from the litterature. The natural history of HCC
>10 cm has been reported at about 2-3 months.Resec-
tion of tumors of this size yielded a median survival of
about 17 months. However, this varied significantly
based on the presence of vascular invasion and satellite
tumors. Median survival with trans-arterial chemo-
embolization ranged from 9-11 months. The outcomes
of ablation and systemic therapies specifically for
tumors >10 cm was very difficult to extract from the
litterature. Surgical resection, when possible, offers the
longest survival reported for patients with HCC
>10 cm. However, treatment with embolization seems
to extend survival beyond the natural history of
patients with tumor of this size.
SY04-1
DEFINITION OF BORDERLINE
RESECTABLE PANCREATIC CANCER
AND PREOPERATIVE DECISION
MAKING FOR RCTABILITYESE
Jason Fleming
The University of Texas MD Anderson Cancer Center,
U.S.A.
Over the past several years, a distinct subset of patients
with pancreatic cancer has been described: patients with
“borderline resectable” tumors. In addition to this
established tumor-specific definition, our evolving expe-
rience with the use of multimodality therapy for
patients with pancreatic cancer has brought to light
two other subsets of patients that may also be consid-
ered “borderline resectable” based on additional clinical
criteria: 1) patients with indeterminate or questionable
metastatic disease at presentation, and 2) patients with
a suboptimal performance status or extensive medical
comorbidities requiring prolonged evaluation that pre-
clude immediate major abdominal surgery. To better
treat these patients we have developed the following
MDACC borderline resectable categories included three
patient subsets as defined by the following clinical and
radiographic characteristics. MDACC Type A: patients
with borderline resectable tumor anatomy as defined
on CT images to include the following findings: 1)
tumor abutment (180˚ or less of the circumference of
the vessel) of the SMA or celiac axis; 2) tumor abut-
ment or encasement (> 180˚ of the circumference of the
vessel) of a short segment of the hepatic artery typically
at the origin of the gastroduodenal artery, or 3) short-
segment occlusion of the SMV, PV, or SMV-PV conflu-
ence which was amenable to vascular resection and
reconstruction because of a patent SMV and PV below
and above the area of tumor -related occlusion.
MDACC Type B: patients with borderline resectable
disease due to the concern for possible extrapancreatic
metastatic disease. This subgroup of borderline resect-
able patients included those with CT findings suspicious
but not diagnostic of metastatic disease, and those with
known N1 disease from either pre-referral laparotomy
or endoscopic ultrasound-guided fine-needle aspira-
© 2014 The Authors
HPB 2014, 16 (Suppl. 2), 3–37 HPB © 2014 Americas Hepato-Pancreato-Biliary Association
Symposium 7
tion. Type B patients may have had a technically
resectable or a borderline resectable primary tumor as
defined on CT images. MDACC Type C: patients with
borderline resectable disease due to a marginal perfor-
mance status (ECOG 3), or those with a better perfor-
mance status and significant pre-existing medical co-
morbidity thought to require protracted evaluation
thereby precluding immediate surgery. Type C patients
may also have had a radiologically resectable or a bor-
derline resectable primary tumor. These patients
receive an initial treatment program of chemotherapy
and/or chemoradiotherapy. Treatment was generally
administered off-protocol, but some patients were trea-
ted on protocols designed for patients with locally
advanced disease. Therapy was administered either at
our institution or under the care of the patient’s refer-
ring oncologist. External-beam radiation therapy was
delivered using either 50.4 Gy in 28 fractions or 30 Gy
in 10 fractions. Concomitant chemotherapy included
5-fluorouracil, paclitaxel, gemcitabine or capecitabine
in radiosensitizing doses. When systemic therapy was
administered, it consisted of gemcitabine alone or in
combination; some patients, particularly those treated
most recently, received targeted agents. The most com-
mon treatment sequence involved 2 to 4 months of sys-
temic therapy followed by chemoradiation with
restaging evaluations every 2 months. Approximately
4 to 6 weeks after the completion of all therapy,
patients underwent restaging evaluation to include CT
and complete physiologic assessment to determine suit-
ability for surgery.
In general, ~40% of borderline resectable patients who
receive preoperative treatment will undergo resection
and no difference in the resectability rate is observed
between different borderline types. Vascular resection
can be expected in about 30% of patients. Surgical
margins are grossly negative in all patients with a
microscopically positive margin in <10% of patients.
Tumor size and lymph node positivity is no different
between Borderline groups. Major postoperative com-
plications occur in about 25% of patients with Border-
line Type C patients more likely to have a longer
recovery. As reported by Katz, et al (J Am Coll Surg.
2008 May; 206(5):833-46), patients who complete all
therapy including surgical resection can experience a
median survival of 40 months and a 5-year survival of
36% (type A: 40 months/40%; type B: 29 months/
46%, type C: 39 months/19%). In contrast, patients
who did not undergo surgical resection of the primary
pancreatic tumor had a median survival of only
13 months (type A: 15 months, type B: 12 months,
type C: 13 months, P < 0.001). In summary, our center
has developed a practical clinical staging of Borderline
resectable patients with pancreatic cancer that sub-
groups them into MDACC Types A, B, and C based
on anatomic and patient factors. We have found it par-
ticularly useful because it draws special attention to
that aspect of the patient’s case which is likely to be
the limiting factor in achieving possible cure. We hope
that others will find this nomenclature useful in clinical
practice and especially for the design of clinical trials
exploring non-surgical therapies delivered pre- or post-
operatively.
SY04-2
WHAT IS THE OPTIMAL
NEOADJUVANT TREATMENT FOR
BORDERLINE RESECTABLE
PANCREATIC CANCER?
Thierry Conroy
Institut de Cancerologie de Lorraine, France
Borderline resectable pancreatic cancer (PC) are tumors
that have limited involvement of the mesenteric vessels
such that resection is technically possible, but with high
risk for margin-positive resection and early local failure
unless neoadjuvant therapy is used before surgery. Dif-
ferent classifications of borderline resectable PC are
available with no uniformly accepted set of criteria for
this definition; however, the concept supposes that
tumor down-staging is needed to achieve R0 resection.
Literature review has been performed to identify papers
and abstracts since 2000. It is generally accepted that
borderline resectable PC should be treated with neoad-
juvant chemotherapy and/or chemoradiotherapy or the
sequential use of both before resection. Several treat-
ment modalities have been investigated in numerous,
often retrospective, small non-randomized studies. Due
to increased response rate with new chemotherapy regi-
mens, including Folfirinox, induction chemotherapy has
been increasingly used. There has been no clear consen-
sus about a regimen that would be most beneficial in
this setting. Nevertheless, there is a consistent finding
that neoadjuvant therapy can induce resectability in up
to 30%–40% of borderline resectable PC patients. Ran-
domized clinical trials are still necessary to determine
the optimal regimen of neoadjuvant therapy in border-
line resectable PC.
SY04-3
TREATMENT OF BORDERLINE
RESECTABLE PANCREATIC CANCER:
SURGICAL TECHNIQUE TO OBTAIN
MARGIN NEGATIVE RESECTIONS
Shailesh Shrikhande
Tata Memorial Centre, India
Borderline Resectable Pancreatic Cancer has emerged
as a distinct clinical entity in recent years. This concept
has enabled pancreatic specialists to further re-classify
the previous term locally advanced pancreatic cancer.
We thus have a group of tumors that are not clearly
and easily resectable on one hand and neither are they
clearly unresectable on the other. In practical terms,
borderline resectable pancreatic cancer is one wherein
superior mesenteric vein-portal vein involvement is
>180 degrees or the gastroduodenal artery is involved
from its origin or < 2 cm of the common hepatic artery
is involved or a combination of the above. Abutment,
but not encasement of superior mesenteric artery, is
also considered as borderline resectable pancreatic can-
cer. There are a number of advances that have evolved
in the treatment of these complex tumors. Surgically,
the focus has remained on a R0 resection and careful
attention given to pancreatic resection margins espe-
cially the posterior retroperitoneal margins. In order to
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achieve this, the superior mesenteric artery first
approach (SMA First) is now widely regarded as the
best approach. The approach can be from different
angles depending on the location of the tumor i.e. pos-
terior, right medial, anterior, superior and left inferior
approaches can be variously employed depending on
whether tumors are large in the uncinated process, or
when they are in the neck-body region of the pancreas
or when vein involvement is known or anticipated.
Thus, this approach is ideal for all vein resections in
borderline resectable pancreatic cancer and also when
there is tumor abutment of superior mesenteric artery.
Another novel approach is to consider neo-adjuvant
treatment prior to considering radical surgery by the
SMA first approach. This invited lecture discusses the
authors institutional experience of borderline resectable
pancreatic tumors and more specifically pancreatic can-
cer – on a backdrop of world literature. Furthermore,
the lecture will aim to update all aspects of surgical
techniques to achieve margin negative resections and
thus improve long term survival of borderline resect-
able pancreatic cancer.
SY04-4
TREATMENT OUTCOMES AND
STANDARDIZATION FOR OPTIMAL
CLINICAL TRIALS
Helmut Friess
Department of Department of Surgery, Technische
Universit€at M€unchen, Germany
Introduction: Following curative resection and adjuvant
chemotherapy patients with pancreatic ductal adenocar-
cinoma (PDAC) have a 5-year survival rate of 20%–
25% and a median survival of 17–28 months. This
compares favourable with the dismal prognosis of
patients with inoperable locally advanced, or metastatic
disease that have a median survival of 8–12 and 3–
6 months, respectively. Multiple series have shown that
extended pancreatic resections for PDAC can be done
with comparable morbidity and mortality rates com-
pared to standard resections at specialised centres.
Therefore, extended resections are recommended by
current guidelines in case of locally advanced or bor-
derline PDAC to improve survival. However, data from
high-quality clinical trials is lacking and frequently bor-
derline PDAC patients cannot be resected.
Method: Evaluating borderline PDAC in clinical trials
raises several problems. As there is no universally
accepted definition of borderline PDAC and inclusion
criteria in available clinical trials are often not stan-
dardized. Depending on the definition employed,
reported rates of borderline PDAC vary between
10%–25%. Borderline definitions should consider: a)
the absence of distant metastasis, b.) involvement of
the portal vein and the superior mesenteric vein, c.)
involvement of the gastroduodenal and hepatic artery
and d.) involvement of the superior mesenteric artery.
An acceptable definition of bordeline resectability well
suited for clinical trials has been proposed by an
international consensus conference and has been
adopted by the U.S. National Comprehensive Cancer
Network.
Results: As resected borderline PDAC patients are at
high-risk for margin-positive resections and early treat-
ment failure following a surgery-first strategy, neoadju-
vant strategies are increasingly employed. However,
response evaluation is difficult due to the extensive des-
moplastic reactions in PDAC, which impedes radio-
logic/morphologic evaluation. Functional response
evaluation procedures like FDG-PET have rendered
conflicting results and are not yet standardized, while
cytologic/histologic response evaluation seems impracti-
cal due to the anatomic difficulties in obtaining biopsies
from the tumour and the high rate of false negative
biopsies due to the stromal reaction.
Furthermore, choosing clinically meaningful endpoints
in borderline PDAC trials is challenging. While some
authors propose R1-resection rate as a feasible end-
point in clinical trials as it has been shown to be a
prognostic factor in some trials others have failed to do
so, mainly because margin clearance is largely depen-
dent on the pathological handling and reporting of
specimens. Following the implementation of standard-
ized pathologic protocols, R1 resection rates of up to
75%–85% have been reported. Similarly, the ratio of
resected/unresected patients in a RCT seems inappro-
priate, as the surgical decision making, the number of
treatment failures in the neoadjuvant arm and the lack
of blinding makes it prone to bias. Therefore, end-
points in borderline PDAC trials should be, from a
clinical and methodological perspective, as persuasive
as for other oncology trials. Regulatory institutions like
the European Medicines Agency (EMA) or the U.S.
Food and Drug Administration (FDA) have unani-
mously published position papers in which overall sur-
vival (OS), progression free survival (PFS) and disease-
free survival (DFS) have been proposed as suitable effi-
cacy endpoints. Furthermore, all trials should address
translational aspects. Modern trial designs with com-
bined phase II/III trials or with adaptive trial designs
should be considered to accelerate progress.
Conclusion: Finally, the advent of effective chemother-
apeutic regimes against PDAC allows to address the
important aspect of patient selection. Induction chemo-
therapy may be used as an appropriate tool to define
borderline PDAC patients who may benefit most from
subsequent resection with or without previous radio-
therapy.
SY05-2
PITFALLS IN CLINICAL TRIAL
DESIGN: BIAS AND CONFOUNDERS
Moo-Song Lee
Ulsan University College of Medicine, Korea
Every clinical research, including clinical trials, has
inherent possibility of biased inference. Bias is defined
as systematic deviation of results or inferences from
truth. Bias usually occurs from study design, selecting
study subjects, study measurement, following study
outcomes, etc. It has several forms, including selection
bias and measurement bias, as well as various other
biases. Confounding, sometimes called confounding
bias, is defined as bias of the estimated treatment effect,
due to baseline differences of prognostic factors
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between treatment groups. In clinical trials, randomiza-
tion and blinding are widely used to minimize biases.
Randomization makes the treatment groups similar to
each other for known and unknown variables, by
which minimizes confounding bias. For observational
clinical research, propensity analysis is usually used to
minimize confounding bias. Blinding is used to avoid
measurement bias as well as placebo effect. As for fol-
lowing up outcomes or treatment effect, follow-up loss
or withdrawal of study subjects should be accounted,
while analyzing study results. For such purpose, inten-
tion-to-treat principle is usually used for statistical
analysis to avoid biases. For this topic, basic concepts
of bias and confounding are introduced as well as some
practical examples in clinical trials.
Reference: Gordis L 2008 A Dictionary of Epidemiol-
ogy 5th Edition. International Epidemiological Associa-
tion 2008 Epidemiology 4th Edition.
SY05-3
HOW TO BUILD BIOLOGICAL
DATABASE FOR RETROSPECTIVE
STUDIES: BIOINFORMATICS
Soo-Yong Shin
Asan Medical Center, Ulsan University, Korea
Due to enormous amount of biomedical publication,
the well-curated biological databases have been essen-
tial for research. However, the quality of the databases
varies significantly, and the specific database which
fully satisfies the research purpose is hard to find.
Therefore, though lots of databases have been already
implemented for research or commercial purposes,
many researchers have tried to build their own databas-
es. TRIP (Transient receptor potential channel-Interact-
ing Protein) Database (http://www.trpchannel.org) will
be introduced to demonstrate how to build the specific-
domain database. As the computational tools, PIE the
search (http://www.ncbi.nlm.nih.gov/IRET/PIE) will be
shown to explain the text mining technologies to curate
the Pubmed literature and BioQRator (http://www.
bioqrator.org) will be proposed to describe the neces-
sity or benefits of the semi-automatic method. Though
text mining methods can extract the necessary informa-
tion from literature, the performance of text mining
tools is still not satisfactory for fully automatic meth-
ods. Therefore, to improve the quality of contents in
the implemented database, manual curation by human
experts is essential up to now. To remove the burden
of human curators, the semi automatic annotation
tools are necessary by supporting tasks such as anno-
tating entities and relationships. Even though there are
lots of database in public or private domain, research-
ers often need new databases for their research. To
build biomedical database, collaboration among IT
experts and domain experts is essential. Domain experts
should define the purpose of database, and curate the
necessary resources such as literature or other databas-
es. IT experts should provide easy-to-use tools for cura-
tion, and implement databases as well as intuitive
interface. A coordinator who can understand the bio-
medical domain and IT domain can be helpful to
improve the collaboration.
SY05-4
HOW TO GET YOUR PAPER
ACCEPTED FOR PUBLICATION
O James Garden
University of Edinburgh, United Kingdom
This presentation will focus on the key elements
required to produce a quality publication. Find a good
mentor or advice regarding your research to ensure
that the work is of sufficemnt quality to be considered
for presentation or publication. Comply with journal
guidelines on preparation of the manuscript. The
mansucript undergoes a review process that determines
whether the content is of sufficent quality to add to the
evidnce base in surgery. Manuscripts must read well
and referees are negatively influenced by a failure to
comply to the journal editorial style and by poor gram-
mar and language. Authors should interpret results
without bias providing balanced and reasoned conclu-
sions that relate to the aim of the study.
SY06-1
OPERATIONAL IMMUNE TOLERANCE
IN LIVER TRANSPLANTATION
George Mazariegos
Children’s Hospital of Pittsburgh of UPMC, U.S.A.
Properties unique to the liver that enhance its tolero-
genic properties have been well documented (1). In clin-
ical practice, operational tolerance (defined as the
absence of destructive allograft injury despite lack of
immunosuppressive therapy) has been described in
patients withdrawn from immunosuppression for emer-
gent, life threatening infectious or malignant indications
as well as by physician-prescribed, protocolized with-
drawal or, rarely, by non- compliance. Historical clini-
cal experience has suggested that between
approximately 20% of carefully selected long term
adult and pediatric liver transplant recipients may be
successfully withdrawn from immunosuppressive medi-
cations and maintain normal liver tests (2). However,
in children in particular, there is substantial literature
documenting the progressive deterioration of liver
architecture including fibrosis over time (3) and concern
that immunosuppression withdrawal might exacerbate
and/or accelerate these changes (4). Several prospective
trials in immunosuppression withdrawal have recently
been reported in both adults and in children (5-7) or
are ongoing. We look to them to advance several criti-
cal research priorities that include delineating the
impact withdrawal on the emergence of alloantibodies
and the evolution of allograft histopathology (8-10),
identifying biomarkers that may predict successful
withdrawal (11-13), and demonstrating the benefit of
immunosuppression withdrawal. Finally, prospective
tolerance induction protocols (14), utilizing either non
myeloablative protocols and/or donor bone marrow
infusion are underway primarily in
References:
1. Levitsky J. Operational tolerance: past lessons and
future prospects. Liver transplantation: official publica-
tion of the American Association for the Study of Liver
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary Association HPB 2014, 16 (Suppl. 2), 3–37
10 Symposium
Diseases and the International Liver Transplantation
Society. 2011;17(3):222–32. Epub 2011/03/09.
2. Mazariegos GV, Sindhi R, Thomson AW, Marcos
A. Clinical tolerance following liver transplantation:
long term results and future prospects. Transplant
immunology. 2007;17(2):114–9. Epub 2007/02/20.
3. Hubscher S. What does the long-term liver allograft
look like for the pediatric recipient? Liver transplanta-
tion : official publication of the American Association
for the Study of Liver Diseases and the International
Liver Transplantation Society. 2009;15 Suppl 2:S19–24.
Epub 2009/10/31.
4. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y,
Egawa H, Yurugi K, Masuda S, et al. Progressive graft
fibrosis and donor-specific human leukocyte antigen
antibodies in pediatric late liver allografts. Liver trans-
plantation : official publication of the American Associ-
ation for the Study of Liver Diseases and the
International Liver Transplantation Society. 2012;18
(11):1333–42. Epub 2012/08/14.
5. Benitez C, Londono MC, Miquel R, Manzia TM,
Abraldes JG, Lozano JJ, et al. Prospective multi-center
clinical trial of immunosuppressive drug withdrawal in
stable adult liver transplant recipients. Hepatology.
2013. Epub 2013/03/28.
6. de la Garza RG, Sarobe P, Merino J, Lasarte JJ,
D’Avola D, Belsue V, et al. Trial of complete weaning
from immunosuppression for liver transplant recipients:
Factors predictive of tolerance. Liver transplantation :
official publication of the American Association for the
Study of Liver Diseases and the International Liver
Transplantation Society. 2013;19(9):937–44. Epub 2013/
06/21.
7. Feng S, Ekong UD, Lobritto SJ, Demetris AJ,
Roberts JP, Rosenthal P, et al. Complete immunosup-
pression withdrawal and subsequent allograft function
among pediatric recipients of parental living donor
liver transplants. JAMA : the journal of the American
Medical Association. 2012;307(3):283–93. Epub 2012/
01/19.
8. Importance of liver biopsy findings in immunosup-
pression management: biopsy monitoring and working
criteria for patients with operational tolerance. Liver
transplantation : official publication of the American
Association for the Study of Liver Diseases and the
International Liver Transplantation Society. 2012;18
(10):1154–70. Epub 2012/05/31.
9. Demetris AJ, Isse K. Tissue biopsy monitoring of
operational tolerance in liver allograft recipients. Cur-
rent opinion in organ transplantation. 2013;18(3):345–
53. Epub 2013/04/27.
10.Yoshitomi M, Koshiba T, Haga H, Li Y, Zhao X,
Cheng D, et al. Requirement of protocol biopsy before
and after complete cessation of immunosuppression
after liver transplantation. Transplantation. 2009;87
(4):606–14. Epub 2009/03/25.
11.Schulz-Juergensen S, Marischen L, Wesch D, Oberg
HH, Fandrich F, Kabelitz D, et al. Markers of opera-
tional immune tolerance after pediatric liver transplan-
tation in patients under immunosuppression. Pediatric
transplantation. 2013;17(4):348–54. Epub 2013/05/23.
12. Gokmen R, Hernandez-Fuentes MP. Biomarkers of
tolerance. Current opinion in organ transplantation.
2013;18(4):416–20. Epub 2013/07/11.
13. Castellaneta A, Thomson AW, Nayyar N, de Vera
M, Mazariegos GV. Monitoring the operationally toler-
ant liver allograft recipient. Current opinion in organ
transplantation. 2010;15(1):28–34. Epub 2009/11/06.
14. Page EK, Dar WA, Knechtle SJ. Tolerogenic thera-
pies in transplantation. Frontiers in immunology.
2012;3:198. Epub 2012/07/25.
SY06-2
NOVEL BIOMARKERS FOR GRAFT
REJECTION AND ADAPTATION
Richard B. Freeman
Dartmouth-Hitchcock Clinic and Geisel School of
Medicine Lebanon, U.S.A
Since the beginning of chemical immunosuppression,
transplant physicians have recognized the need for eval-
uating the effectiveness of this therapy. This is critically
important since clinicians can alter the dose and inten-
sity of immunosuppression to revers rejection episodes.
For this reason there has been wide inters in developing
methods to diagnose rejection. Unfortunately up until
recently, the only adequate sensitive and specific
method has been by biopsy of the transplant organ.
Allograft biopsy though low risk, does pose the risk for
complications, is inconvenient and potentially uncom-
fortable for patients and carries costs. In this review, I
will summarize recent work in several areas using both
new and not os new technologies to meet the challenge
of diagnosing rejection and graft function without inva-
sive tests. Most of these methods now rely on simple
blood or urine tests. For brevity, I will review three
main areas, gene expression and regulation in blood
cells, measurement of circulating immune response
markers such as DSA, and newer metabolomics or pro-
teomic markers.
The future for much more specific, personalized, less
invasive measurement of allograft function an the
immune response thereto is bright and will improve the
outcomes and quality of life for our recipients.
SY07-1
ANATOMICAL LIVER RESECTION
BASED ON PREOPERATIVE 3D
SIMULATION
William C. Chapman
Washington University in St. Louis, U.S.A
Today decisions regarding major hepatectomy are
based in large part on cross-sectional imaging usually
with contrast-enhanced CT or MR imaging. This two-
dimensional imaging can now be easily reconstructed in
a three-dimensional framework including major vascu-
lar and biliary tract structures. This three-dimensional
imaging can then be actively utilized for preoperative
resection planning including precise calculation of the
future liver remnant as well as planned resected liver
volumes. In addition, assessments of tumor margin as
well as functional whole and future remnants based on
the non-tumor bearing liver have become a standard
and are possible to be calculated in an automated fash-
ion. There are a number of imaging systems available
allowing for these preoperative planning methods. In
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addition, operative guidance is now able to be achieved
using tracked instruments during the course of the
operative procedure. These details will be discussed in
the course of this presentation.
SY07-2
MRI-BASED ASSESSMENT OF HEPATIC
FUNCTIONAL RESERVE
Eduard Jonas
Karolinska University Hospital, Sweden
Postoperative mortality following liver resection is low
with many centres reporting mortality rates <1%. Cur-
rently, the largest cause of postoperative mortality after
liver resection is liver failure. In patients with healthy
liver parenchyma, a future liver remnant (FLR) >20%
of the total estimated functional liver volume is usually
sufficient to sustain postoperative liver function and
enable regeneration. In patients with normal liver func-
tion, the FLR is assessed in terms of volume measure-
ments only, commonly using computed tomography
(CT) or MRI. However, many patients being consid-
ered for resection do not have normal liver paren-
chyma. This problem is common in patients with
hepatocellular cancer (HCC), with the majority of
tumours occurring in patients with cirrhosis and com-
promised liver function. With increasing use of neo-
adjuvant and downstaging chemotherapy in multimo-
dality treatment plans for patients with colorectal can-
cer liver metastases (CRCLM), chemotherapy-
associated liver injury (CALI) is more frequently
encountered in this patient group and has shown to be
association with increased morbidity and even mortal-
ity after resection. In patients with decreased liver func-
tion, the minimum volume of the FLR has to be
increased according to the level of parenchymal damage
and associated liver dysfunction. Current methods for
liver function assessment include routine laboratory
tests measuring surrogate markers (serum bilirubin,
albumin, coagulation factors, etc), scoring systems com-
bining biochemical and clinical information (e.g.,
Child-Pugh and Model for end-stage liver disease
[MELD] scores) and quantitative liver function tests
(e.g., indocyanine green [ICG] clearance, albumin syn-
thesis tests, LiMAx). The use of liver function tests for
preoperative assessment varies worldwide and regional
algorithms for HCC treatment strategies include differ-
ent combinations of liver function assessment methods,
with non-adherence to guideline recommendations
being common. Current methods for assessing liver
function, as outlined above, measure global function,
with no consideration for segmental variations in func-
tion or dysfunction. However, in a number of condi-
tions, including cirrhosis and CALI, function is not
homogeneously distributed throughout the liver. This
can result in over- or underestimation of the function
in the FLR. Overestimation puts patients in danger of
post-operative liver-failure, whereas underestimation
may deny some patients potentially curative surgical
treatment. Thus, there is a need to develop more
sophisticated methods sensitive to regional differences
in function. Imaging-based functional liver analyses
have the potential to provide more accurate, multi-
compartmental measurements, generating a multitude
of function and perfusion parameters on a segmental
or sub-segmental, allowing clinicians to detect and
account for inhomogeneous distribution of parenchy-
mal function. A number of hepatobiliary scintigraphic
methods using [99mTc]-labeled iminodiacetic acid deri-
vates or galactosyl serum albumin have shown good
correlation with ICG clearance, but is hampered by
poor anatomical resolution. MRI has, apart from its
diagnostic capabilities, excellent anatomic resolution,
useful for treatment planning and volumetry. Func-
tional data regarding parenchymal architecture and
fibrosis can also be obtained by including sequences
enabling elastography and relaxometry in protocols.
Gadoxetic acid is a hepatocyte-specific MRI contrast
used for detection and characterization of focal liver
lesions. Pharmaco-kinetically it follows pathways simi-
lar to ICG and iminodiacetic acid for hepatic uptake
and excretion making it a potential substrate for func-
tional analysis.
SY07-3
FLUORESCENT IMAGE-GUIDED LIVER
SURGERY
Norihiro Kokudo
Graduate School of Medicine, the University of Tokyo,
Japan
Recently, in vivo fluorescent imaging using indocyanine
green (ICG) has been applied in clinical settings for
visualization of the bile ducts (fluorescent cholangiogra-
phy) and identification of hepatic tumors during open
and laparoscopic hepatobiliary surgery. In the tech-
nique of fluorescent cholangiography, ICG solution
(0.025 mg/mL) is injected directly into the bile duct (in-
trabiliary injection). The intrabiliary-injection technique
is useful for identification of the confluence between the
left and right hepatic ducts during hemi-hepatectomy.
For the delineation of bile duct anatomy during chole-
cystectomy, 2.5 mg of ICG is intravenously injected at
least 15 min prior to the observation. In our previous
series of laparoscopic cholecystectomy, fluorescent chol-
angiography visualized the confluence between the cys-
tic duct and the common hepatic duct in 75% of
patients before the dissection of Calot’s triangle and in
93% of patients after the dissection. For the intraoper-
ative fluorescence imaging of hepatocellular carcinoma
(HCC) and liver metastasis, the ICG that was adminis-
tered intravenously at the dose of 0.5 mg/kg for preop-
erative liver function testing can be utilized as a
fluorescence source. Intraoperatively, fluorescence
images of hepatic tumors are visualized on the liver
surfaces only by using commercially-available fluores-
cence imaging system. On the cut surface of the
resected specimens, most of the differentiated HCCs
show fluorescence of ICG in cancerous tissues, while
majority of the poorly differentiated HCCs and liver
metastases appear as rim-fluorescing tumors (fluores-
cence of ICG is visualized not in the cancerous tissues
but in the surrounding non-cancerous liver paren-
chyma). Recently, genetic analysis and immunohisto-
chemical staining has elucidated mechanistic
background of the ICG-fluorescence imaging of hepatic
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tumors: in differentiated HCC tissues, portal uptake of
ICG by NTCP and OATP8 is preserved but there exists
disordered biliary excretion of ICG, leading to accumu-
lation of ICG in cancerous tissues at the time of sur-
gery. In contrast, in poorly differentiated HCCs and
liver metastases, ICG is not taken up into cancerous
tissues but retains in the non-cancerous hepatic paren-
chyma compressed by the tumor, as a result of bile
excretion disorders. This technique is clinically useful
as an intraoperative navigation tool, which enables
real-time identification of peripherally-located but
grossly unidentifiable small hepatic tumors and visuali-
zation of residual HCC tissues on the raw surface of
the liver. ICG-fluorescence imaging also enables estima-
tion of portal uptake function in veno-occlusive regions
of the liver. In this technique, ICG (0.0025 mg per
1 mL of remnant liver volume) is intravenously admin-
istered following closure or reconstruction of the major
hepatic veins. Then, fluorescent intensity on the liver
surfaces, which represents ICG concentration in each
hepatic region, is measured using fluorescence imaging
at 5 minutes after the injection of ICG. This technique
provides surgeons with quantitative information on
functional decrease in veno-occlusive regions in each
patient, which may further enhance safety of major
hepatectomy and liver transplantation.
SY07-4
NEW TECHNIQUE AND INSTRUMENT
Nagy Habib
Imperial College London, United Kingdom
Despite advances in surgical technique, liver resection
still frequently results in significant blood loss with
many patients requiring blood transfusion peri- or
postoperatively. Although allogeneic blood transfusion
is generally considered to be safe, there are still associ-
ated risks including immunosuppression, incompatible
transfusion and transmission of infectious agents.
Patients requiring intraoperative blood transfusions
during liver resection for HCC and CLM have been
shown to have a poorer long-term prognosis. In addi-
tion, intraoperative bleeding during liver resection
increases postoperative morbidity. To address this we
developed a bipolar radiofrequency (RF) device, the
Habib 4X, used specifically for hepatic parenchymal
transection. Between 2001 and 2010, 604 consecutive
patients underwent liver resections with the RF assisted
technique. There were 206 major and 398 minor hepa-
tectomies. Median intraoperative blood loss was 155
(range 0e4300) ml, with a 12.6% rate of transfusion.
There were 142 patients (23.5%) with postoperative
complications; none had bleeding from the resection
margin. Only one patient developed liver failure and
the mortality rate was 1.8%. Li et. al. recently pub-
lished a randomised controlled trial (RCT) in which 75
cirrhotic patients with HCC who underwent hepatec-
tomy were randomized to RF assisted using Habib 4X
(group 1, n = 38) or clamp crush (CC) (group 2,
n = 37) groups. The blood loss of the RF assisted
group, total or during transection, was significantly
lower than that of the CC group (385 vs. 545 ml,
P = 0.001; 105 vs. 260 ml, P = 0.000, respectively).
Compared with CC patients, the morbidity of the RF
assisted group was lower though not statistically signifi-
cant (28.9 vs. 38.8 %, P = 0.197). RF assisted liver
resection allows major and minor hepatectomies to be
performed with minimal blood loss, low blood transfu-
sion requirements, and reduced mortality and morbid-
ity rates.
SY08-1
SCREENING FOR PANCREATIC
CANCER: GOLD OR DROSS?
Sean Mulvihill
University of Utah, U.S.A.
Pancreatic adenocarcinoma is the fourth leading cause
of cancer mortality in the United States yet comprises
only 3% of new cancer diagnoses each year. Despite
marked improvement in medical care leading to
decreased incidence and mortality in some commonly
diagnosed cancers, similar changes have not been seen
in pancreatic cancer. An opportunity exists to increase
survival through improved screening methods that
allow for the detection of early stage pancreatic cancers
amenable to surgical resection. Earlier stage tumors
have better prognosis and treatment of pancreatic
tumors discovered incidentally appears to be associated
with prolonged survival, supporting the possible sur-
vival benefit with early diagnosis of pancreatic cancer.
This review summarizes our current understanding of
pancreatic cancer in the context of screening and early
detection and explores characteristics of an optimal
screening approach, including identification of high risk
patients, identification of appropriate biomarkers with
high diagnostic sensitivity and specificity, and second-
ary screening with imaging.
SY08-2
HOW TO MANAGE PAINFUL CHRONIC
PANCREATITIS
Martin D Smith
University of the Witwatersrand, Johannesburg, South
Africa
The treatment of Chronic Pancreatitis (CP) remains a
challenge. We have a better understanding of the path-
ophysiology of pain in CP and as such our understand-
ing of the role for the different procedures has
improved. There is however a long list of possible pro-
cedures reflecting the difficulty in treating this condi-
tion. We have however confirmed that the concept of
pancreatic burnout after years of the disease is not an
option for these patients.
The goals of treatment are clear. 1. Relief of pain; 2.
Control of local complications; 3. Preservation of func-
tion; 4. Social and occupational rehabilitation; 5
Improve quality of life 6. Exclude malignancy. Unfor-
tunately there is no uniformly accepted measure of out-
come. Morbidity and mortality, while important
outcomes only partially reflect the goals of treatment.
It is recommended that a validated quality of life
(QOL) tool such as the QLQ C40 be used in conjunc-
tion with standard reporting of surgical outcomes.
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The surgical options can be divided into 3 main groups.
Resection alone (pancreaticoduodenectomy (PD))
Drainage alone (Puestow type pancreatico jejunostomy)
or a Combination of resection and drainage (Frey/
Beger procedure)
The resection only procedure has a higher morbidity
although the mortality has improved. They provide
good pain relief but the pancreatic function is adversely
affected. Distal resections should be avoided as the
pain relief is not good and the functional deterioration
is significant. The pancreatico-jejunostomy has been
extensively studied in case controlled observational
studies and while there are reported series with good
pain relief overall there is a high rate of pain recur-
rence. The combination procedures first introduced by
HG Beger have been widely studied and this included
RCT comparing the various combination procedures
with the PD. The basic principles include local resec-
tion of the head of the pancreas with duodenal preser-
vation. The RCT have small cohorts of patients but the
results are compelling. While they show improved early
results with the Frey compared to the Beger procedure
they also show improved morbidity compared to the
PD. However the long term results up to a mean follow
up of 15 years suggest there is no statistically signifi-
cant difference between these procedures in terms of
pain relief and functional outcomes. Our unit performs
the Frey type procedure and our results in over 100
patients will be presented.
A number of questions remain un-answered. How
much coring out of the head is required? What is the
best approach to the strictures and dilated duct in the
body and tail? And what is the best approach to man-
age the dilated obstructed biliary tree. Our own
approach is to combine a hepaticojejunostomy to the
same Roux limb. The results with the re-implantation
of the CBD into the cored out head of the pancreas
has been shown to have a high recurrence rate for
obstructive jaundice, while there is almost no recur-
rence with our approach
Recent RCT comparing endoscopic therapy with sur-
gery for CP have shown that the results with surgery
are superior. Endoscopic therapy, in particular EUS
remains valuable in the treatment of pseudocysts and
for the complications of obstructive jaundice. The role
as definitive therapy for painful CP is limited. However
in some patients early endoscopic therapy of ductal
stones may produce good results. As this therapy has
low morbidity rates and does not “burn any surgical
bridges” it may be the first intervention is select
patients.
Recent data explores the timing of surgery in CP. Early
surgery results in reduced opiate use which has been
shown to be a predictor of worse outcome. The rela-
tionship between substance abuse disorder including
opiate addiction is circular in that major depression
disorder linking these disorders aggravating the disease
and making outcomes worse. In addition recent evi-
dence from Japan has suggested that early surgery may
reduce the prevalence of pancreatic duct adenocarci-
noma. The mechanism for this is not clear but the data
is again compelling.
The role of alcohol abstinence in preventing the recur-
rence of pain following surgery for CP has mixed evi-
dence. In some series including our own continued
alcohol consumption was associated with better QOL
outcomes. What is well described is the negative impact
of ongoing smoking on long term outcomes. We advise
our patients to significantly reduce their alcohol con-
sumption but to stop smoking completely. Avoidance
of high risk occupations with exposure to the petro-
chemical industry to mention just one is also important
in the preservation of the pain relief achieved with sur-
gery.
In conclusion we have a better understanding of the
pathophysiology of pain in CP. In addition the results
of studies comparing surgery to endoscopic therapy
support a surgical approach. There seems little to
choose between the resection and combined procedures
and currently local expertise and experience should
guide the choice of procedures. Any concerns about
malignancy in CP should, if feasible be managed by
resection. The improved QOL in most series suggest
surgical therapy should be offered to patients with
painful CP and that there is no place for a nihilistic
approach by waiting for “burn out” to occur.
SY08-3
RECENT UPDATE IN MANAGEMENT
OF PANCREATIC CANCER
Roland Andersson
Lund University, Sweden
Pancreatic cancer is one of our most dismal prognoses,
responsible for one fourth of deaths in cancer. Only
maximum 15 % are candidates for surgical resection
with radical attempt at the time of diagnosis while
about 50 % have locally advanced disease and the
remaining already metastases to not at least the liver.
During the last 15 years, the most evident improvement
has been the effect of adjuvant chemotherapy following
surgical resection, rendering a median survival of some
20–22 months. The overall survival rate is about 7–
8 months and the 5-year survival in ductal pancreatic
adenocarcinomas less than 2 %. The need for improve-
ment both in more accurate and not at least early diag-
nosis as well as more effective treatment is thus urgent.
Novel tools for diagnosis, prognosis and prediction-
making will be covered, including new tumor-specific
biomarker panels (for both tissue and blood), artificial
neural networks and proteomic profiles to be used for
diagnosis and also potentially in risk group patients
e.g. hereditary conditions and new onset diabetes type
2. The state-of-the-art surgical procedure as comes pros
and cons of various parts of pancreatic resection will
be presented in order to render the “optimal” surgical
procedure, minimizing morbidity and mortality, factors
influencing upon them. Recent new chemotherapeutic
combinations have rendered some improvement in the
outcome in patients with pancreatic ductal adenocarci-
noma. This is though not enough as up to now most
treatment regimes have been based upon gemcitabine, a
nucleoside receptor necessary for the intracellular incor-
poration of the chemotherapeutic agent but expressed
only in about one third of the patients. Health econom-
ical aspects will be described. The need for novel,
tumor-specific and personalized treatment regimes will
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be described including radioimmunotherapy and nano-
immunoliposomes carrying substances directed both at
the tumor and its stroma. The challenge to improve
outcome in pancreatic cancer is enormous and requires
completely novel diagnostic and interventional tools.
The lecture will cover state-of-the-art management and
frontline research towards a hopefully brighter future.
SY08-4
ASSESSING THE BURDEN OF MAJOR
PANCREATIC RESECTION USING THE
POSTOPERATIVE MORBIDITY INDEX
(PMI)
Charles Vollmer
University of Pennsylvania, U.S.A.
Postoperative complications are traditionally reported
by incidence, but not quantified. The postoperative
morbidity index (PMI) is derived using two validated
systems: ACS-NSQIP and the Accordion Severity
Grading System, for which quantitative complication
severity weights were previously derived by expert opin-
ion. This study compares the burden of complications
and presents the morbidity spectrum of common pan-
creatic operations. Nine American centers contributed
ACS-NSQIP complication data for 2308 pancreatic
resections from 2005–2011. Each complication was
assigned one of six previously established Accordion
severity weights ranging from 0.11 for the least severe
complication (grade 1) to 1.00 for postoperative death
(grade 6). The PMI reflects the sum of complication
weights for all complications divided by the total num-
ber of patients. PMI can range from 0 (no complication
in any patient) to 1.00 (all patients died of complica-
tions). Contribution to total burden of complications
by each complication grade was also derived and dis-
played in a severity “spectrogram”. The PMI and spe-
cific morbidity profile were compared between proximal
(PD), distal (DP), and total (TP) pancreatectomies.
ACS-NSQIP complications occurred in 712 cases
(30.9%). The frequency of complications differed sig-
nificantly (P = 0.002) between the three types of proce-
dures (Table) and Grade 2 complications were highest
in frequency. There were 30 deaths for a mortality rate
of 1.3%. The PMI for all pancreatectomies in the series
was 0.109. The most common complication contribut-
ing to the PMI for each operation was Organ Space
Infection (7.8% overall). The spectrogram for major
pancreatectomy illustrates the difference between fre-
quency and burden of different complication grades.
DPs were significantly less morbid than were either
PDs (P = 0.001) or TPs (P = 0.028). This was due to
a higher occurrence of grade 5/6 (multiorgan failure/
death) complications contributing to more burden in
PD and TP. Conversely, Grade 2/3 complications pro-
vided a greater contribution in DPs. PD did not differ
from TP (P = 0.214). There was significant variation in
PMI by institution for PD (P < 0.001), but not for
other procedures. Variation also existed among individ-
ual surgeons for PD and DP. Subgroup analysis reveals
the PMI of DP did not vary based on laparoscopic vs.
open approach or the performance of splenectomy, but
did increase with the addition of colon resection. The
PMI of TP increases with age. The complication bur-
den in complication-bearing patients only was also
examined; there was no difference among the proce-
dures. This study establishes quantitative benchmarks
for morbidity of common pancreatic operations. It
illustrates the fact that frequency of complications does
not equate to their burden. The PMI provides an objec-
tive means of comparing the impact of types and
grades of complications across various operations.
SY09-2
LIVER RE-TRANSPLANTATION FOR
HCV RECURRENCE
Umberto Cillo
Chirurgia Epatobiliare E Trapianti Epatici, Italy
Hepatitis C virus (HCV) infection is the most common
indication for liver transplantation (LT) worldwide.
However, HCV infection recurs universally after LT and
fibrosis progression is accelerated in the graft. The med-
ian time to cirrhosis, estimated from clinical studies, is
>30 years in immunocompetent individuals with HCV.
By contrast, approximately 10–30% of HCV patients
develop cirrhosis within 5 years post transplant, with
the majority of HCV patients developing graft cirrhosis
by 9–12 years post transplant. These patients also
develop liver decompensation more quickly than their
non-transplanted HCV-infected counterparts, with
approximately 50% of patients with HCV graft cirrhosis
experiencing an episode of decompensation during
12 months of follow up, and <50% surviving a further
12 months. This rate of decompensation is much greater
than that seen in non-transplant HCV cirrhosis, which is
approximately 28% by 10 years of cirrhosis.
Around 30% of patients develop aggressive HCV
recurrence, leading to rapid fibrosis progression (RFP)
and culminating in liver failure and either death.
Retransplantation (RT) is the only therapeutic option
to achieve long-term survival in patients with decom-
pensated cirrhosis after LT, but it is now well accepted
that patients with HCV recurrence post transplant do
poorly with retransplantation, which is associated with
3-year survival rates in the order of only 50%. This is
particularly true for patients with severe hepatitis C
recurrence (cholestatic hepatitis) and forms with rapid
fibrosis progression (RFP). However, a wide variability
in terms of short and long term results has been
reported in the different published series.
Furthermore, it is not clear whether RFP in the first
graft will be followed by the same rate of fibrosis pro-
gression in the second graft.
Strategies to improve the outcome of RT for HCV
include:
1. Prevention of severe hepatitis C recurrence could be
the first step to avoid RT. Active management of fac-
tors which can accelerate fibrosis progression (donor
age, post- transplant diabetes, high dose of corticoster-
oids) might reduce the incidence of severe forms of
hepatitis C recurrence.
2. Identifying patients at higher risk of RFP to improve
timing of anti-viral therapy after first LT or to antici-
pate RT. Several studies have underlined the role of
metabolic factors, such as insulin resistance, in HCV
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recurrence. Moreover, emerging data have identified
genetic markers of HCV recurrence useful for predict-
ing adverse outcomes.
3. The use of prognostic scores as screening tools has
shown an improvement in survival in HCV-infected
patients after RT, reaching similar survival rates as
those obtained in non HCV- infected patients. These
scores can identify, in fact, candidates with a high risk
of mortality in whom the use of a new organ would be
unreasonable.
On the light of the recent availability of new inter-
feron-free anti-viral drugs, the scenario of RT for HCV
recurrence will change dramatically. Antiviral treatment
on the waiting list (if possible) and early identification
and treatment of patients with severe hepatitis C recur-
rence could become a good strategy to avoid RT. In
cases of inevitable RT, the use of these new drugs
could limit the impact of HCV recurrence on post-RT
outcome.
Prospective comparative trials should be set in the next
future to address these particular issues in the light of
such an epocal breakthrough.
SY09-3
SELECTION OF PATIENT FOR
COMBINED LIVER & KIDNEY
TRANSPLANTATION IN
HEPATORENAL SYNDROME
Geoffrey McCaughan
RPAH/University Of Sydney, Australia
Chronic Endstage Liver Disease can be associated
with Renal disease/ Kidney Failure via 2 main mecha-
nisms.Firstly the underying cause of the liver failure
may aslo cause structural kidney disease .Examples of
this include Adult polycystic disease, Peadiatric dis-
eases ( Congenital Liver Fibrosis ) Hepatitis B/ and C
, Amyloid .The second main association is via the
Hepatorenal syndrome. Also, of course, Chronic
Renal Failure may occur in patients with Chronic
Liver Failure via independent disease processes. In
general Combined Liver and Kidney Transplantation
is universally offered to patients with Combined Liver
Failure and Kidney Failure who are on heamodialysis
due to structural kidney disease.The major controversy
is wether combined transplantation should be offered
to pateints with the Hepatorenal sydnome on dialysis.
Current ILTS guidelines recommend that combined
transplantation should only be offered in the HRS
when the patient has been on dialysis for > 6 weeks
and there is no evidence of recovery .This is based on
evidence that Renal recovery can occur post liver
transplantation when the time frame is < 6 weeks .The
controversy lies in several issues -(1) many patients
with HRS can not be supported re liver failure for
this peroid of time (2) Renal physcians remain reluc-
tant to allocate organs away from long standing dialy-
sis patients to Liver Failure patients (3) Some
patients recover renal function despite being on dialy-
sis for > 6 weeks (4) It has been advocated that these
patients should just recieve Liver Transplants and if
they do not recover then go onto Kidney tarsnpalnt
waiting lists. The presentation will outline the risks
and benefits re these issues and why current ILTS
guidelines seem reasonable
SY09-4
PORTAL INFLOW MODULATION IN
SMALL-FOR-SIZE GRAFT SYNDROME
IN LDLT: DOES IT WORK?
Seiji Kawasaki
Juntendo University, Japan
In the field of adult-to-adult living donor liver trans-
plantation (LDLT), the successful application of portal
inflow modulation has recently led to renewed interest
in the use of a left lobe graft which is inevitably small-
for-size. However, data on hepatic hemodynamics sup-
porting portal inflow modulation are limited, and the
optimal portal circulation for a liver graft is still
unclear. My experience included 145 adult-to-adult
LDLTs using left lobe graft without either splenectomy
or portocaval shunt at Shinshu University (1990.6–
2002.9) and Juntendo University (2003.7–2013.10). We
accept donor-recipient combinations giving predicted
ratios between graft volume and standard liver volume
(GV/SV) of equal to or more than 30%. Significance
of left lobe grafts and postoperative courses and sur-
vival of the recipients were investigated. In addition,
hepatic hemodynamics was analyzed in recent cases at
Juntendo University. In 145 LDLTs using left lobe, the
graft volume ranged from 230 to 625 ml. The actual
GV/SV ratio varied from 26 to 65% and was less than
40% in 72 cases. The actual graft-to-recipient body
weight ratio (GRBWR) was less than 0.8% in 58 recip-
ients. In our cases, the mean portal venous pressure
was not significantly changed after transplantation as
compared to that when the native liver existed. The
portal pressure after graft implantation was more than
20 mmHg in 23 out of 32 cases, and higher than
15 mmHg in 31 out of 32 cases. Neither portocaval
shunting or splenectomy was performed in any case of
our series. Mean post-transplant portal vein flow
expressed as total mL/min per 100 g graft was
301  157 mL/min/100 g graft weight in 40 recipients
in whom PVF was measured. A weak negative correla-
tion was observed between the GV/SV ratio and the
portal venous flow/100 g graft weight. The smaller the
graft, the higher the portal flow. The portal venous
flow was more than 260 mL/min/100 g graft weight, a
poor prognostic value reported by Shimamura and oth-
ers, in 23 out of 40 cases, maximum 833 mL/min/100 g
graft weight. Patient survival after left lobe graft
LDLT in our series of 145 adult patients was 91% at
1 year and 86% at 5 years. If limited to 51 adult
patients who underwent LDLT at Juntendo University,
all were discharged from hospital in spite of portal hyp-
erperfusion, and the overall 1-, 3-, and 5-year patient
and graft survival rates were 100%, 98%, and 95%,
respectively. GV/SV ratio less than 40%, GRBWR less
than 0.8%, portal flow more than 260 ml/min/100 g
graft weight, or portal pressure higher than 15 or
20 mmHg after graft implantation is not a value for
contraindication or poor outcome. The left liver graft-
ing without portal venous modulation may be applica-
ble more frequently than has been previously supposed.
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SY10-1
CONTINUOUS PARENCHYMAL
SUTURE TECHNIQUE IN
DUCT-TO-MUCOSA
PANCREATICOJEJUNOSTOMY
Sun-Whe Kim
Seoul National University Hospital, Korea
Different types of pancreaticojejunostomy after pancre-
atoduodenectomy have been tried. The current tech-
nique of my department is end-to-side anastomosis
with two layer-method: duct-to-mucosa and continuous
outer layer suture. We have reported that continuous
suture was better than interrupted suture for outer
layer of the pancreaticojejunostomy (World J Gastro-
enterol, 2007). Briefly summary is as below. A: The
posterior outer layer consisted of the remnant pancre-
atic parenchyma and the seromuscular layer of jejunum
and continuous suture between these two was per-
formed with 5-0 polypropylene (Prolene*, Ethicon,
Somerville, NJ); B: The posterior inner layer consisted
of the pancreatic duct and mucosa of the jejunum, and
interrupted suture for duct-to-mucosa was performed
with 5-0 polydioxanone (PDSTMII, Ethicon, Somer-
ville, NJ); C: A silastic polyethylene tube was inserted
into the pancreatic duct and external drainage was
done; D: For anterior inner layer consisted of the pan-
creatic duct and mucosa of the jejunum, interrupted
suture was performed; E: Continuous suture for ante-
rior outer layer was performed. Continuous suture
method for the outer layer of pancreaticojejunostomy
will be shown by video presentation. Continous suture
is a safe and time saving procedure compared to inter-
rupted suture for outer layer suture of pancreaticojej-
unostomy.
SY10-2
A SIMPLE AND SAFE ANASTOMOSIS
FOR PANCREATOGASTROSTOMY
USING ONE BINDING PURSE-STRING
AND TWO TRANSFIXING MATTRESS
SUTURES
Volker Fendrich
University Marburg, Germany
Pancreatic anastomotic leakage remains a persistent
problem after pancreaticoduodenectomy (PD), espe-
cially in the presence of a soft, nonfibrotic pancreas. A
modified technique for pancreatogastrostomy was
devised, which combines one binding purse-string and
two transfixing mattress sutures between the pancreatic
stump and the posterior gastric wall. His technique was
applied in 35 patients after PD for malignant and
benign diseases of whom 10 (28.6%) had a soft pan-
creas. Median time for the anastomosis was 18 minutes.
Operative mortality was zero, and morbidity was
34.3%. Three (8.6%) patients developed a pancreatic
fistula (2 type A, 1 type B) as classified according to
the International Study Group on pancreatic fistula.
All fistulas resolved without further intervention. The
described technique is a simple and safe reconstruction
procedure after PD that warrants further evaluation.
SY10-3
BINDING
PANCREATICOJEJUNOSTOMY
VERSUS BINDING
PANCREATICOGASTROSTOMY
Shu You Peng
The Second Affiliated Hospital Zhejiang University
School of Medicine, China
Binding Pancreaticojejunostomy (BPJ) has been widely
used clinically .However, if the pancreas stump is too
large, it might be difficult to be inserted into the lumen
of jejunum. In order to solve this problem, Binding
Pancreaticogastrostomy (BPG) was developed by the
authors. Both procedures are compared. operative tech-
nique for BPG: 1.Isolation of pancreatic stump for
2 cm 2.Pre-place a purse-string suture at the posterior
gastric wall around the area where an incision will be
made and the pancreatic stump will be inserted into
3.An incision is made at the anterior gastric wall
through which the pancreas stump is pulled into the
gastric lumen via the posterior gastric opening. There-
after, the pre-placed purse-string is tied. From Nov.
2009 to Jan. 2012, 136 cases from 6 centers were
enrolled in a prospective double-blind, randomized con-
trolled trial, and divided into two groups: BPJ group
and BPG group. Pre-operative parameters, serious
complications were evaluated and assessed. There were
totally 53 cases in BPJ group and 83 in BPG group,
with no significant differences in baseline parameters
between two groups. For the intraoperative index, such
as blood loss, blood transfusions, pancreatic texture,
pancreatic free length and main duct diameter of resid-
ual pancreas, there were no significant differences(P
> 0.05). In BPJ group, PF occurred in 6 cases (11.3%),
DGE in 5, hemorrhage in 1, biliary fistula in 2 and
abdominal abscess in 1. One patient died of MOF
caused by abdominal abscess. In BPG groups, PF
developed in 5 cases (6.0%), DGE in 11, hemorrhage
in 3, biliary fistula in 5 and abdominal abscess in 2. No
patient died in BPG group. No statistical difference
was found between two groups with respect to PF rate.
Both BPJ and BPG are safe and reliable procedures for
reconstructing pancreatico-digestive continuity after
PD.
SY10-4
PANCREATICOGASTROSTOMY AFTER
DISTAL PANCREATECTOMY: A CLUE
TO PREVENTING POSTOPERATIVE
PANCREATIC FISTULA
Yasushi Hashimoto
Hiroshima University, Japan
Postoperative pancreatic fistula (PF) has consistently
been regarded as the major source of morbidity after
distal pancreatectomy. The incidence of a clinically-rel-
evant PF is still high with a mean incidence of 15% (9–
23%) according to the definition of the International
Study Group of Pancreatic Surgery (ISGPS). Fistula
formation is multifactorial in nature, influenced by
patient-specific anatomic features of the pancreas and
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operative techniques at the time of resection. In efforts
to prevent PF, surgeons have used sealants, staplers,
and a variety of stump closure techniques that have not
been successful in the prevention of leakage. To
decrease this persistent observation of a 15% clinically-
relevant PF rate, we might view the problem with a
mechanistic view – the stump has not been adequately
closed which is form of pancreatic stump occlusion fail-
ure.
A study into this area showed no difference in occur-
rence of postoperative PF or morbidity between stapler
and hand-sewn closer of the remnant, the only RCT
being the multi-center German trial (Lancet 2010; P
= 0.56, 32% vs 28% PF rate, respectively). Besides
these surgical techniques, several innovative interven-
tions have been proposed to decrease pancreatic ductal
pressure via putting a transpapillary pancreatic stent
before or during surgery which could facilitate the heal-
ing of the pancreatic stump. The ideal of this approach
is that increased intrapancreatic duct pressure might
overcome the quality of the stump closure. To look for
clues for the development of PF, we hypothesized that
drainage of the pancreatic stump into the stomach
through pancreaticogastrostomy may decompress the
intrapancreatic duct pressure and protective against fis-
tula development when compared to hand-sewn or sta-
ple closure. In addition, this approach may provide
more effective sealing of the interrupted smaller ductal
branches on the pancreatic cut surface when we com-
pared with a transpapillary drainage. Since 2008, we
started a prospective cohort study with a pancreaticog-
astrostomy after distal pancreatectomy, forming our
experimental group, and examined its safety and effi-
cacy of this method comparing to a retrospective con-
trol group undergoing hand-sewn closure. The aim of
this study is to analyze the safety and efficacy of this
method. In 2011, we reported the excellent outcomes
for the first 21 patients underwent distal pancreatec-
tomy using the duct-to-mucosa pancreaticogastrostomy:
0% of a clinically-relevant grade B/C PF rate and 29%
of the biochemical grade A PF rate (Am J Surg 2011).
And now we expanded more cases of this approach,
the technical details including various modifications in
the anastomosis will be shown as video presentation.
Prevention of postoperative PF development after pan-
createctomy is a formidable task, but can be success-
fully performed in highly specialized centers doing high
volume of laparoscopic and open pancreatic resections.
Results thus obtained in our 6 years’ experience
showed excellent outcomes with that of hand-sewn or
stapler closure with the added advantage of relatively
simple and minimal invasive approach to the patient.
We hope that this approach will be effective against PF
development through diverse mechanisms in selected
patients. Results of ongoing trials comparing pancreat-
icogastrostomy versus hand-sewn closure technique are
eagerly awaited, and further research into this area is
necessary to make further progress. Improved postop-
erative outcomes should open new areas of research on
complications and long-term survival.
SY10-6
PREDICTION AND MANAGEMENT OF
PANCREATIC ANASTOMOSIS FAILURE
AFTER PANCREATODUODENECTOMY
Michael B. Farnell
Mayo Clinic College of Medicine, USA
Risk factors for clinically relevant pancreatic anasto-
motic failure (CR-PAF) can be grouped into three cate-
gories: patient characteristics, operative factors and
characteristics of the pancreas. Patient characteristics
include weight loss, high body mass index, and sarcope-
nic obesity. Operative factors such as operating time,
blood loss, use of optical magnification, type of anasto-
mosis (pancreaticojejunostomy, pancreaticogastrosto-
my, dunking) have all been implicated as risk factors
for CR-PAF. Pancreatic gland factors associated with
CR-PAF include texture, duct size, absence of fibrosis,
and fatty infiltration. Preoperative abdominal com-
puted tomography (CT) to assess either body composi-
tion or the presence of pancreatic fibrosis and magnetic
resonance imaging estimates of pancreatic fat content
are accurate predictors of CR-PAF.
The 10 point Fistula Risk Score (FRS) based upon
four recognized risk factors for CR- PAF (duct size,
pancreatic texture, high risk pathology, excessive blood
loss) is simple to use, has been externally validated and
is useful for clinical application. Increasing FRS (1–10)
correlates well with development of CR-PAF.
The author’s preference for pancreaticoenteric anasto-
mosis is end-to-side duct-to-mucosa pancreaticojejunos-
tomy. A surgical drain is routine. Pancreatic duct
stenting is no longer employed. Enteric feeding tubes,
somatostatin analogs, and dunking anastomosis are
used only rarely and highly selectively.
When CR-PAF occurs, our approach is to provide fluid
resuscitation, broad spectrum antibiotic therapy and
nutritional support. Abdominal CT is used to assess
source control and placement of percutaneous drains if
indicated. There should be vigilance for the develop-
ment of delayed post pancreatectomy hemorrhage
(PPH), and if confirmed, visceral angiography with
embolization or stent placement should be performed
emergently. Reoperation is reserved as a rescue strategy
when sepsis from poor source control or bleeding
refractory to endoscopic or interventional radiologic
(IR) techniques develops.
In a recent 5-year period, the author performed 281
consecutive open pancreatoduodenectomies (PD)
(2004–2009). CR-PAF occurred in 36 (12.8%). In spite
of the routine placement of a surgical drain, the major-
ity of the patients with CR-PAF required placement of
image-guided percutaneous drains. Reoperation for
PAF was required in only 4 (11%) of the 36 patients
with PAF. Postoperative hemorrhage occurred in 14
(5%): 5 were managed with IR, 7 with endoscopy and
2 with reoperation. Reoperation was limited to wash-
out and establishment of wide peripancreatic drainage.
Completion pancreatectomy was not performed. Opera-
tive mortality for the 281 patients was 1.1%.
Early and aggressive source control has improved the
outcome for patients with CR-PAF. Currently, the
most feared complication of CR-PAF is delayed PPH.
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At the author’s institution from 2002–2012, 1430 PDs
were performed. Thirty-two patients (2%) required IR
control of delayed PPH, a median of 26 days following
operation. The median number of units of RBCs trans-
fused was 5. Forty-two procedures were required in the
32 patients: embolization 27, stent 14, balloon dilation
of endoleak 1. The reoperation rate in the 32 patients
was 37% due to need to control sepsis. The mortality
rate was 12%.
Models based upon analysis of preoperative imaging
and intraoperative scoring systems have made risk
assessment of CR-PAF quite accurate. Techniques to
decrease the rate of CR-PAF in high risk patients are
needed. The management of CR-PAF has improved
with image-guided percutaneous drain placement and
interventional radiologic control of delayed post pan-
createctomy hemorrhage. Reoperation should be
reserved as a rescue strategy.
SY11-1
RADIOLOGIC STAGING: PITFALLS
AND PRACTICAL LIMITATIONS
Cher Heng Tan
Tan Tock Seng Hospital, Singapore
GB cancer (GBCA) is often first recognized on imag-
ing, as an unexpected or incidental finding, given that
patients may often present with non-specific clinical
symptoms that may be similar to other gallbladder dis-
eases. To make diagnosis more difficult, this condition
is notoriously non-specific on imaging on many occa-
sions, particularly in its early stages. This can at times
lead to delayed diagnosis and incurable disease. GBCA
shows numerous imaging features that overlap with a
large number of benign conditions. In this lecture, we
shall review the typical morphologic features of GBCA
(mass-forming, wall thickening, polypoid) on imaging.
More importantly, the atypical features of this condi-
tion and the similarities that it may possess with benign
gallbladder diseases, such as cholecystitis, adenomyo-
matosis and benign polyps will be discussed. To com-
plete the understanding of the pitfalls and practical
limitations of radiological staging of GBCA, the
strength and limitations of each of the main cross-sec-
tional imaging modalities, specifically ultrasound, CT
and MRI for imaging of GBCA will be reviewed.
SY11-2
NEW CONCEPT OF PATHOLOGY:
INTRACHOLECYSTIC PAPILLARY-
TUBULAR NEOPLASM OF
GALLBLADDER
Volkan Adsay
Emory University Hospitals, U.S.A.
The literature on the clinicopathologic characterics of
tumoral intraepithelial neoplasms (neoplastic polyps) of
the gallbladder (GB) is fairly limited, due in part to the
variability in definition and terminology. Most
reported adenomas (pyloric gland-type and others)
were microscopic and thus regarded as clinically incon-
sequential, whereas, wheras papillary in-situ carcinomas
have been largely considered as type of invasive adeno-
carcinoma under the heading of “papillary adenocarci-
noma”. In a recent study, we analyzed 123 GB cases
that formed a well-defined exophytic preinvasive neo-
plasm measuring ≥1 cm were analyzed. The patients
were predominantly female (F/M = 2:1) with mean age
of 61, and median tumor size of 2.2 cm. Half of the
patients presented with pain, and in the other half, the
neoplasm was detected incidentally. Other neoplasms,
most being GI tract malignancies, were present in 22%.
Gallstones were identified in only 20% of cases. Radio-
logically, almost half were diagnosed as “cancer,”
roughly half with polypoid tumor, and in 10% the
lesion was missed. Pathologic findings: I. The predomi-
nant configuration was papillary in 43%, tubulopapil-
lary in 31%, tubular in 26%. II. Each case was
assigned a final lineage type based on the predominant
pattern (>75% of the lesion) on morphology, and sup-
ported with specific immunohistochemical cell lineage
markers. The predominant cell lineage could be identi-
fied as biliary in 50% (66% of which were MUC1 + ),
gastric foveolar in 16% (all were MUC5AC+), gastric
pyloric in 20% (92% MUC6 + ), intestinal in 8%
(100% CK20 + ; 75% CDX2 + ; 50%, MUC2 + ), and
oncocytic in 6% (17% HepPar+ and 17% MUC6 + );
however, 90% of cases had some amount of secondary
or unclassifiable pattern and hybrid immunopheno-
types. III. Of the cases that would have qualified as
“pyloric gland adenoma,” 21/24 (88%) had at least
focal high-grade dysplasia (HGD) and 18% had associ-
ated invasive carcinoma. Conversely, 8 of 47 “papillary
adenocarcinoma” type cases displayed some foci of
low-grade dysplasia (LGD) and 15/47 (32%) had no
identifiable invasion. IV. Overall, 55% of the cases had
an associated invasive carcinoma (pancreatobiliary
type-58; others-10). Factors associated significantly with
invasion were the extent of HGD, cell type (biliary or
foveolar), and papilla formation. Among systematically
analyzed invasive carcinomas, tumoral intraepithelial
neoplasia was detected in 6.4% (39/606). V. The 3-yr
actuarial survival was 90% for cases without invasion
and 60% for those associated with invasion. On the
other hand, those associated with invasion had a far
better clinical outcome than pancreatobiliary GB carci-
nomas (3-yr survival, 27%), and this survival advan-
tage was independent of size and stage of invasion.
Death occurred in long-term follow-up even in a few
non-invasive cases (4/55; median 73.5 months) empha-
sizing the importance of long-term follow up. In con-
clusion, tumoral preinvasive neoplasms (> 1 cm) in
the GB are analogous to their pancreatic and biliary
counterparts (biliary intraductal papillary neoplasms,
pancreatic IPMNs and intraductal tubulopapillary
neoplasms). They show variable cellular lineages, a
spectrum of dysplasia and a mixture of tubular or
papillary growth patterns, often with significant over-
lap, warranting their classification under one unified
parallel category, intracholecystic papillary-tubular
neoplasm (ICPN). ICPNs are relatively indolent neo-
plasia with significantly better prognosis than pancre-
atobiliary type GB carcinomas. On the other hand,
even seemingly innocuous examples such as those
referred to as “pyloric gland adenomas” can progress
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to carcinoma and be associated with invasion, as well
as fatal outcome.
SY11-3
SURGICAL MANAGEMENT FOR GALL
BLADDER CANCER: WHAT IS AN
ADEQUATE RESECTION?
Anil Agarwal
GB Pant Hospital & MAM College, India
Introduction: Gall Bladder Cancer (GBC) is an aggres-
sive tumor and has a propensity to infiltrate adjacent
organs like the liver, hepatoduodenal ligament (includ-
ing the bile ducts, hepatic artery and portal vein), gas-
troduodenum, pancreas, and colon; in addition to
metastasizing to the lymph nodes and distant organs.
While presence of distant metastases indicates inoper-
ability, disease confined to the gall bladder, adjacent
viscera/liver and locoregional lymph nodes may be
amenable to surgical resection. The most important
tenet is to perform an R0 resection of the tumor, with
an acceptable postoperative morbidity.
Method: Surgery for GBC limited to the gall bladder
involves liver resection and loco-regional lymphadenec-
tomy. The liver resection most often involves a bi-sub-
segmentectomy (Segments IVb/V); however literature
supports that a wide wedge of adjacent liver may also
be oncologically adequate in patients with no liver infil-
tration. For extensive hepatic infiltration or vascular
involvement usually an extended right hepatectomy
needs to be performed. The standard lymphadenectomy
involves lymph nodal dissection along the entire length
of the hepatic artery starting from the celiac axis to the
level of its bifurcation into the right and left hepatic
arteries, dissection of the retropancreatic lymph nodes,
and lymph nodal clearance of the hepatoduodenal liga-
ment including the pericholedochal and peri/retroportal
lymph nodes. Thus clearance of nodes from the hepa-
toduodenal ligament, anterior and posterior to the head
of the pancreas and the hepatic artery till its origin
from the celiac axis is achieved.
Para-aortic, superior mesenteric and celiac lymph
nodal involvement is indicative of disseminated disease
(precluding resection) and extended lymphadenectomy
to include these lymph nodal regions is not recom-
mended. Interaorotocaval lymph node is subjected to
frozen section histopathological analysis to prior to
proceeding for radical surgery and resection abanda-
oned in cases with a positive N2 lymph node.
Although the 7th edition TNM classification for GBC
includes retropancreatic nodes along with periaortic,
pericaval, superior mesenteric artery, retropancreatic,
and/or celiac artery lymph nodes as N2 (metastatic)
disease, this may be a drawback as many studies have
reported long-term survival following resection in
patients with involved peripancreatic lymph nodes. We
routinely include these peripancreatic nodes in resec-
tion. A few authors have proposed routine excision of
the extrahepatic bile duct (EBD) to help lymph nodal
clearance of the hepatoduodenal ligament, however,
enough evidence in the literature now to suggest that
routine excision of the EBD does not improve survival
and may add to the morbidity.
Results: Advanced GBC involving adjacent structures
merits more extensive surgery aimed at achieving an R0
resection. Surgical management of GBC infiltrating the
HDL is challenging. Patients with a patent biliary con-
fluence (block distal to it) can usually be managed by a
parenchyma preserving surgery (Sub-segmentectomy
IVb/V), while those with hilar separation are most
often managed by an extended right hepatectomy. In
these patients it is of utmost importance to optimize
the future liver remnant by performing a preoperative
biliary drainage (endoscopic/percutaneous), portal vein
embolization (when required), and considering segment
IVa preservation. The tumor may infiltrate the hepatic
artery (common/right), or the portal vein (main/right).
Right portal pedicle infiltration is managed by an ipsi-
lateral hepatectomy (extended right hepatectomy). Iso-
lated right hepatic artery (RHA) involvement may be
treated by either resecting and reconstructing the RHA
or just by ligating and sacrificing it, provided that there
is no obstruction to the right portal vein, more so when
it (RHA) is found to be already completely blocked at
surgery and on division there is some backflow from
the distal stump. Limited main portal vein involvement
can be managed by a sleeve portal vein resection; more
extensive portal infiltration requires either a portal vein
resection with an end-to-end anastomosis or an inter-
position graft. Involvement of the proper hepatic artery
by the tumor is usually considered to be a contraindica-
tion to resection by most surgeons.
Tumors especially in the fundus and body of the gall
bladder infiltrate adjacent viscera like the duodenum,
colon and the pancreas. Some surgeons consider locally
advanced GBC involving adjacent viscera a sign of un-
resectability while others consider it as an indication
for more extensive resections ranging from resection of
the adjacent viscera and upto a hepatopancreaticoduo-
denectomy (HPD). Current evidence suggests that
involvement of adjacent viscera in GBC does not pre-
clude resection and provides better outcomes in those
who undergo an R0resection. Limited involvement of
the duodenogastric region does not warrant an HPD
and an R0 resection can be achieved by limited excision
of the involved viscera. In patients with limited gastro-
duodenal involvement, a sleeve resection can be done,
while in those with more extensive duodenal involve-
ment (without pancreatic infiltration) a distal gastrec-
tomy with proximal duodenectomy (DGPD) can be
performed. DGPD includes resection of a variable
length of the first and suprapapillary portion of the sec-
ond part of the duodenum (depending upon the extent
of duodenal involvement). Patients with colonic
involvement can be managed with either a sleeve resec-
tion or a segmental colonic resection depending upon
the extent of infiltration. Wedge resection of the pan-
creas is an alternative to HPD in patients with limited
pancreatic infiltration. In our experience, as for several
Japanese centres, HPD is reserved for GBC patients
with extensive duodenopancreatic involvement, exten-
sive peripancreatic lymphadenopathy which cannot be
cleared without pancreatoduodenctomy and locally
advanced GBC with diffuse biliary involvement.
Conclusion: In summary the surgical management of
GBC, a radical cholecystectomy, is performed which is
an oncologically radical procedure, the extent of which
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varies depending upon the location of tumor and adja-
cent organ involvement; aimed at achieving an R0
resection with adequate locoregional lymph nodal clear-
ance.
SY11-4
ROLE OF POSTOPERATIVE ADJUVANT
TREATMENT FOR ADVANCED
GALLBLADDER CANCER
Woo-Jin Lee
National Cancer Center, Korea
Gallbladder cancer (GBC) is an uncommon but highly
fatal malignancy. Though surgical resection has been
the only option for cure, the majority of these patients
present with advanced disease, which precludes surgical
resection. Furthermore, even after complete resection,
outcomes are poor, particularly for T3 and/or node-
positive disease.Thus, effective postoperative adjuvant
therapy is required to prolong survival in patients with
GBC undergoing surgery. However, no standard post-
operative treatment has been established as yet. There
is no firm basis to recommend an adjuvant approach in
GBC. The rarity of gallbladder cancer has traditionally
precluded large randomized trials, and the literature
abounds with small case series and retrospective com-
parisons that attempt to address whether adjuvant che-
motherapy and/or radiation therapy are beneficial after
complete resection. Despite the lack of proven efficacy,
adjuvant treatment, particularly radiotherapy, is recom-
mended and used frequently. This practice has been
promoted on the basis of the findings of a number of
small single institution, non-randomized studies sug-
gesting a survival benefit of adjuvant therapy to resec-
tion of GBC.
1. Patterns of disease recurrence In contrast to patients
who have margin-positive resections, in whom locore-
gional recurrences predominate, the pattern of disease
recurrence following complete resection of GBC is dis-
tant plus local. In a study from MSKCC, 85% of
recurrences included distant sites as part of the recur-
rence pattern, highlighting the importance of systemic
therapies. In our hospital study, after resection, recur-
rent GBC and intrahepatic cholangiocarcinoma (IHC)
are more likely to involve a distant site and associated
with shorter TTR than recurrent extrahepatic cholan-
giocarcinoma (EHC). The median times to distant
recurrence in the GBC and IHC groups were shorter
than that in the EHC group. These findings collectively
suggest that an adjuvant therapeutic strategy targeting
distant disease, such as chemotherapy, is likely to have
a significant impact on the overall management of
GBC and IHC. 2. Benefits of adjuvant therapy In light
of the available data, it is reasonable to consider
patients with high-risk lesions (T2-4 tumors, at least
one positive lymph node, R1 resection) for adjuvant
therapy. 1) Radiation and chemoradiotherapy The role
of adjuvant radiation therapy (RT) in the treatment of
GBC is not well established. Among patients undergo-
ing potentially curative resection, postoperative external
beam RT can diminish local recurrence rates, but the
lack of randomized trials makes it difficult to ascertain
whether survival is favorably impacted. Impressions of
a survival advantage have been reported in many retro-
spective reports in which either RT alone or chemora-
diotherapy (generally with a concomitant
fluoropyrimidine) was administered. A recent SEER
database analysis of 4000 patients with gallbladder can-
cer found a survival benefit with adjuvant radiotherapy
in patients with positive nodal disease or T2 or greater
tumors (15 months vs. 8 months). This difference was
significant on multivariate analysis (HR = 1.46; 95%
CI, 1.07 to 1.98; p = .014). However, it is entirely possi-
ble that the apparent survival prolongation was attrib-
utable to selection of fitter patients for adjuvant
therapy and/or tumor biology and was unrelated to the
use of RT. Furthermore, most series included only
small numbers of patients, and many incorporated dif-
ferent sites of the biliary system (GBC plus cholangio-
carcinoma), making it difficult to draw meaningful
conclusions regarding management of GBC. The bene-
fit of adjuvant RT has been challenged by some other
studies.
2) Chemotherapy alone The pattern of disease recur-
rence in completed resected GBC, in which the major-
ity of patients have distant failure as a component of
initial disease recurrence, suggests that chemotherapy
might be a more rational adjuvant treatment strategy
than RT or chemoradiotherapy alone. Although retro-
spective series have suggested some degree of benefit
from adjuvant chemotherapy, the performance of pro-
spective trials has been limited by the lack of effective
agents.
SY12-1
WHAT STRATEGY TO PROPOSE FOR
SYNCHRONOUS COLORECTAL LIVER
METASTASIS
Chris Christophi
University of Melbourne, Australia
Up to 25% of patients with colorectal cancer will pres-
ent with synchronous liver metastases. These patients
pose therapeutic challenges in determining the optimum
sequence for surgery of the primary tumour and liver
metastases. Patients should initially be thoroughly
staged including MRI-CT scans of chest and abdomen
and FDG-PET scan and CEUS intra operatively. Ide-
ally most patients should undertake perioperative che-
motherapy to improve survival outcomes and
determine tumour biology. Patients undertaking che-
motherapy who develop progressive disease may thus
avoid subsequent laparotomy. Patients who present
with obstruction may require stenting prior to com-
mencement of chemotherapy.
Surgical options include delayed or simultaneous resec-
tion of the primary and liver disease, either by laparo-
scopic and/or open techniques. The conventional
approach is resection of the primary, followed by che-
motherapy and delayed hepatectomy in patients who
do not demonstrate disease progression of liver disease
during interval chemotherapy. The major disadvantages
include the requirement for two procedures and poten-
tial delay between the two procedures due to operative
complications. It is indicated in patients with significant
comorbidities, with bleeding or obstructive (unable to
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be stented) symptoms, rectal tumours or advanced liver
disease.
The simultaneous approach to resection of both the pri-
mary tumour and liver metastases has been advocated
in highly selected patients depending patient co-morbid-
ity and the extent and site of disease. These include
patients requiring minor liver resection of less than
three liver segments and extra rectal primary lesions. In
these patients, postoperative complications, operative
mortality, overall and recurrence free survival appear
comparable to the conventional staged resections.
There is a decreased operative time, hospital stay and
possibly decreased blood loss in this group. In small
series, the laparoscopic approach to simultaneous resec-
tion appears to have equivalent results to the open
approach.
In situations where hepatic disease is most dominant
and the primary tumour is relatively asymptomatic,
a”liver first” approach may be utilised. The response
to chemotherapy and disease progression is a critical
factor in the decision making. Mortality rates and sur-
vival appear variable.
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SY12-3
COMBINED PREOPERATIVE
CHEMOTHERAPY AND SURGERY OF
COLORECTAL LIVER METASTASES
Rene Adam
APHP Ho^pital Paul Brousse, France
Despite the extension of surgical indications, resection
is an initial option for only 10–20% patients, and most
patients with hepatic metastases present with unresec-
table disease. In patients with resectable metastases,
perioperative oxaliplatin-based chemotherapy (FolFox)
has been demonstrated to increase the 3-year disease-
free survival after resection. However, with extended
follow-up, no increase in overall survival has been
observed. Due to the increased risk of postoperative
complications in patients submitted to chemotherapy,
the routine indication of preoperative chemotherapy is
now challenged especially for single metastases. This is
not the case for patients with initially unresectable
metastases. Systemic chemotherapy is the common
treatment in this condition with recently, an impressive
improvement in both rates of response and survival
and the objective of secondary resection after downsiz-
ing. This improvement related to the use of oxaliplatin
and irinotecan, is presently amplified by the combined
used of anti EGFR (epidermal growth factors) agents
such as cetuximab and panitumumab and anti-VEGF
agents (vascular endothelial growth factor) such as bev-
acizumab. However, the increase in median survival
with all these combined agents, still little impacts long-
term survival in the absence of surgery. Therefore,
strategies for treating initially unresectable disease
include conversion chemotherapy aimed at downsizing
the metastases and making them suitable for resection.
Resectability rates now reach at least 30 % of unresec-
table patients with 5-year survival rates of around 35%
at 5 years. To further increase the resectability rate of
initially unresectable patients, specific techniques such
as portal embolisation, radiofrequency ablation com-
bined with resection, and two-stage hepatectomies
including ALPSS (Associated Liver Partition with Por-
tal ligation for Staged hepatectomy) are presently avail-
able. Overall, the onco-surgical concept to combine
chemotherapy and surgery is increasingly accepted as
the best mean to improve the prognosis of advanced
metastatic colorectal cancer.
In patients who relapse following hepatectomy, repeat
resections if potentially curative, can give the same sur-
vival benefit, with a risk of operative mortality as low
as that of the first liver resection.
In summary, while merely palliative in the past, the
treatment of colorectal cancer metastatic to the liver is
currently switching to a search of long-term remission
by combining the improved results of surgery and that
of chemotherapy. Strategies are becoming more
« agressive » and multidisciplinary, resulting in a signif-
icant gain in survival of many patients promised in the
past, to a very poor outcome.
SY12-4
MANAGEMENT OF MISSING
COLORECTAL LIVER METASTASIS
AFTER CHEMOTHERAPY
Michael Choti
UT Southwestern Medical Center, U.S.A.
Preoperative chemotherapy affords significant potential
advantages in patients with hepatic colorectal metasta-
ses, either as neoadjuvant therapy or as conversion
therapy to increase the number of patients eligible for
surgical therapy. However, one potential disadvantage
may be related to the impact of chemotherapy on the
accuracy of preoperative imaging. For example, the
presence of chemotherapy associated steatosis can sig-
nificantly affect the sensitivity of preoperative CT or
MRI detection of liver metastases. Moreover, small
liver metastases can shrink and disappear while on che-
motherapy, further complicating the management of
these patients. Studies have demonstrated that while
these lesions might become completely invisible on
post-chemotherapy CT scans, viable tumor cells are
present in over 80% of these disappearing metastases.
Other studies have shown that viable tumor cells were
present in approximately half of all disappearing lesions
(vanVledder et al). In this study, disappearing metasta-
ses were common in patients undergoing preoperative
chemotherapy, with approximately one fourth of
patients having at least one lesion disappear. When
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carefully assessed intraoperatively, approximately 50%
of these lesions were detected with IOUS. Moreover,
overall survival was not significantly affected if some of
these disappearing liver metastases were left surgically
untreated, possibly due to the opportunity of these
patients to undergo repeat surgical intervention when a
recurrence in these untreated lesions was observed dur-
ing follow-up. However, it is generally recommended
to completely resect or ablate all disease sites as known
prior to chemotherapy, to prevent early recurrence and
the need for re-operation. In order to minimize the risk
of facing the dilemma of missing metastases that can-
not be identified, consideration of preoperative MRI
imaging is helpful, as studies demonstrate increased
sensitivity following preoperative chemotherapy. Specif-
ically, patients with small lesions being treated with
preoperative chemotherapy, MRI should be considered
as the imaging modality of choice, particularly with dis-
appearance on CT. Careful assessment of the location
of every lesion prior to chemotherapy should be deter-
mined and attention directed to these areas during sur-
gery.
SY13-1
FELLOWSHIP PROGRAM FOR HPB
SURGERY
Wan Yee Lau
The Chinese University of Hong Kong, Hong Kong,
China
Hepatopancreatobiliary (HPB) surgery has developed
into an established subspecialty in General Surgery in
the 1980s. With further development of HPB surgery
towards the two extremes, with minimal invasive sur-
gery on one end and extensive and heroic surgery on
the other end, the current practice of HPB surgery dif-
fers significantly in different parts of the World. While
in developing countries, HPB surgery is still carried out
by general surgeons, in developed countries it is carried
out mainly by HPB surgeons. This obviously produces
difference in results for complicated HPB cases and
there is a demand for better trained HPB surgeons all
around the world.
In 2006, under the presidency of Dr. Henry Pitt, a reg-
istry was available on the IHPBA website for HPB fel-
lowship training. There were 56 Fellowship programs
from 18 countries in 5 continents. At the same time,
the IHPBA Education and Training (E&T) Committee
was created with a mission to establish a set of require-
ments for HPB training for standardization of HPB
training, and to ensure the provision of high quality fel-
lowship training for IHPBA members.
In 2008, the E&T Committee developed the standards
for HPB fellowship training and the curriculum for
HPB training and these have since been put on the web
for the IHPBA.
In 2011, an article entitled “Evaluation of HPB fellow-
ships, an international survey of programme directors”
was published (HPB 2011;13:279-85). In this survey, 71
program directors from centers around the World were
approached and 40 directors responded. The result
showed a great diversity among centers regarding
requirement for application, the duration of training
and exposure to HPB cases during the fellowships, and
recommendations were made to improve the future
training program.
The IHPBA Kenneth W. Warren Foundation was
incorporated in July 2006 to support recipients to carry
out animal or laboratory research on HPB diseases in a
country outside of the recipient’s own country. So far
10 recipients from 10 countries have benefited from this
Foundation. HPB surgery has evolved into a subspe-
cialty which required a special training program to pro-
duce qualified HPB surgeons. IHPBA has contributed
to provide the requirements for such a training pro-
gram.
SY13-2
EDUCATIONAL AND TRAINING
PROGRAMS TO CONSIDER FOR LIVER
TRANSPLANTATION
William C. Chapman
Washington University in St. Louis U.S.A
Current strategies for advanced training in liver trans-
plantation are critical for the successful development of
skilled surgical workforce in this field. This training
should consist of a minimum of 18–24 months of com-
bined training including didactic course work and
attainment of practical skills in the field of liver trans-
plantation. This should be combined with a practical
graded progression of responsibility during the course
of liver transplant procedure so that at the completion
of training the trainee is able to independently perform
all the components associated with liver transplantation
including independent performance of donor organ
recovery. Minimum numbers of transplant procedures
should be achieved for the trainee acting as first assis-
tant or surgeon during the operation. This includes
organ back bench preparation, donor hepatectomy,
and the implantation phase of the procedure. We
believe a critical component is the combined inclusion
of advanced HPB training with a special focus on liver
surgery. This portion includes performance of major
hepatectomy, biliary tract reconstruction, and addi-
tional associated procedures such as pancreas resection.
Attention to major vascular reconstruction is a key
component of this training. Programs without sufficient
case volume should probably not be actively engaged
such advanced training, and instead trainees should
work with other higher volume centers. Upon comple-
tion of satisfactory training the program director
should certify satisfactory competence in the areas of
complex case management including preoperative
workup and assessment as well as postoperative care
and immunosuppression management.
SY13-3
BECOMING A LAPAROSCOPIC HPB
SURGEON
Nick O’Rourke
Royal Brisbane Hospital, Australia
Being a Laparoscopic HPB surgeon is the best job in
all of medicine, if not in all the world! One gets to look
after nice people with real problems, and help them
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with less painful interventions, to improve the quality
and length of their life. What could possibly be a better
job? Obviously a good surgeon needs to be well edu-
cated in the basics of anatomy, physiology, and pathol-
ogy, as well as develop a deep understanding of HPB
disease. We should all strive to be “physicians who can
operate”, and never mere technicians, following the
advice of lesser mortals, like gastroenterologists. Path-
ways to this pinnacle of medical careers vary interna-
tionally, but all are evolving as laparoscopy becomes
more incorporated into general surgical training. (I will
spend some time talking about our current advanced
HPB traning in Australasia.) Also, the ultimate practice
profile of a laparoscopic HPB surgeon, will vary from
country to country, and from academic to public to
private practice. Ideally, one should have a broad lapa-
roscopic general surgical experience, followed by train-
ing in HPB surgery, combining the two, as you train,
or afterwards. I feel sorry for those surgeons who
missed this pathway, but greatly respect the many open
HPB experts who have succeeded at advanced laparos-
copy without it. I do worry about the other route.
Should good laparoscopic general surgeons, tackle
advanced HPB cases? No. Not without HPB training
or assistance. Once an HPB surgeon is established, I
believe they should do all available laparoscopic HPB
cases, including gall bladders (as well as the occasional
hernia and appendix!). This builds skills and exposes
them to new technology and tricks, which can be incor-
porated into their HPB practice
What about the surgeon at the beginning of his train-
ing? One should embrace laparoscopic general surgery
whenever possible; scrub in whenever it’s on and be the
enthusiast who encourages the boss to keep going lap!
Read and write and present and publish. Become a
video expert by practicing and editing, a lot. Teach oth-
ers your new skills. Never be afraid to ask a question
or challenge a dogma. Most of all, befriend your
patients. You will be the one that laparoscopic HPB
program directors fight over, to have on their team,
because you will be the one to make this great specialty
even better.
SY14-1
CYSTIC NEOPLASM OF THE LIVER
Reid B. Adams
University of Virginia Health System, U.S.A.
Cystic lesions of the liver are common, but these are
comprised of a heterogeneous group of entities. As
such, cystic lesionis can pose a diagnostic dilemma, and
consequently, difficulty developing a treatment plan.
While most are benign and remain so, a small propor-
tion can cause. Discussed in presentation. This discus-
sion will focus on characterizing and differentiating
cystic lesions of the liver. Management decision mak-
ing will be discussed. The need for, timing of, and type
of treatment will be reviewed.
SY14-2
BENIGN SOLID TUMORS AND
PSEUDOTUMORS OF THE LIVER
Yoh Zen
King’s College Hospital, United Kingdom
A variety of conditions are included in this category.
They are quite variable in size, incidence, and clinical
features. For example, bile duct adenoma is usually
subcentimeter and incidentally found in the subcapsular
area, while hepatocellular adenoma forms large masses
that are detectable by imaging. From the histological
point of view, some lesions consist of epithelial cells,
while the others are made of mesenchymal or lymphoid
cells.Benign solid liver tumors / pseudotumors:
- Hepatocellular: Hepatocellular adenoma, Focal
nodular hyperplasia
- Biliary: Bile duct adenoma, Biliary adenofibroma
- Mesenchymal: Angiomyolipoma, Hemangioma,
Solitary fibrous tumor, Mesenchymal hamartoma
- Others: Inflammatory pseudotumor, Pseudolympho-
maThe talk will be focused on hepatocellular adenoma
and inflammatory pseudotumor, as our knowledge of
these two conditions has been advanced in the last dec-
ade.
Hepatocellular adenoma: Recent studies have enabled
us to classify hepatocellular adenomas into several sub-
groups based on genotypic and phenotypic features.
Inflammatory hepatocellular adenoma is the most com-
mon subtype (>50%), pathologically characterized by
an inflammatory infiltrate, sinusoidal dilatation, and
bile ductular reaction. Expressions of serum amyloid A
(SAA) and C-reactive protein (CRP) are another char-
acteristic feature, giving a high diagnostic value. This
subtype was supposedly diagnosed as focal nodular
hyperplasia in the past based on the presence of bile
ductular components. HNF1alpha-inactivated hepatocel-
lular adenoma is characterized by mutations of the
HNF1alpha gene. This type of hepatocellular adenoma
histologically shows diffuse steatosis and the lack of
inflammation and nuclear atypia. The expression of L-
FABP (liver fatty-acid binding protein) is significantly
down regulated in the tumor, as its expression is regu-
lated by HNF1alpha. Beta-catenin-activated hepatocellu-
lar adenoma is rare (~10%). This type has an increased
risk of malignant transformation. Histologically,
nuclear atypia and pseudoglandular growth pattern are
frequently noted. It is often challenging to discriminate
beta-catenin-activated hepatocellular adenoma from
well differentiated hepatocellular carcinoma. On immu-
nostaining, beta-catenin is expressed in nuclei and glu-
tamine synthetase is diffusely expressed in the
cytoplasm of tumor cells. Less than 10% of hepatocel-
lular adenoma lacking specific features is called
“unclassified”.
Inflammatory pseudotumor: Hepatic inflammatory
pseudotumor is known to occur in relation to locore-
gional or systemic inflammatory reaction. Since the
concept of IgG4-related disease was proposed, growing
evidence has suggested that inflammatory pseudotumor
is linked to IgG4-related disease. However, it is impor-
tant to note that hepatic inflammatory pseudotumors
are not always IgG4-related. Inflammatory pseudotu-
mors can be classified into several subtypes based on
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histological features. Between the two major subtypes
(lymphoplasmacytic and fibrohistiocytic) of hepatic
inflammatory pseudotumors, the former corresponds to
IgG4-related disease. This lymphoplasmacytic type is
characterized by periductal mass lesions typically
involving hilar / perihilar ducts. Radiological features
are reminiscent of those of hilar cholangiocarcinoma,
which has led to unnecessary surgical resections. Most
reported cases of inflammatory pseudotumors associ-
ated with “primary” sclerosing cholangitis likely belong
to this category. Steroid therapy is very useful. The fi-
brohistiocytic type, which is not related to IgG4, is
characterized by an extensive xanthogranulomatous
reaction. This subtype more commonly exhibits masses
within the peripheral liver parenchyma in contrast to
the lymphoplasmacytic type in which hilar / perihilar
tissue is typically involved. Whether or not steroid ther-
apy is effective in this type remains uncertain. Another
less common subtype that has turned out to be a true
neoplasm is now called inflammatory myofibroblastic
tumor as evidenced by the fascicular proliferation of
atypical spindle cells against a background of inflam-
matory cell infiltration. Surgical resection is the treat-
ment of choice for this tumor. Recent studies on
hepatocellular adenoma and inflammatory pseudotu-
mor have given us useful information about their sub-
classification scheme, biological nature, and association
with other conditions.
SY14-3
MANAGEMENT OF LIVER HYDATID
CYST: WHERE IS THE EVIDENCE?
Chadli Dziri
Charles Nicolle hospital, Tunisia
Hydatid cyst of the liver is a very common disease in
endemic area and it is still a serious health problem. This
lecture aimed to provide evidence based answers to the
following questions: 1) should chemotherapy be used
alone or in association with surgery? 2) What is the best
surgical technique? 3) Laparoscopic or open approach?
4) When is the percutaneous aspiration injection and rea-
spiration technique (PAIR) indicated? 5) What are fac-
tors predicting recurrence in the era of laparoscopic
approach? Conclusions of this lecture were based on: 1) a
systematic review (1) published in 2004, 2) a retrospective,
multicenter cohort study (from 35 Tunisian academic
and community hospitals of General Surgical Depart-
ments which participated to this study between January
1st 2001 and December 31st 2005) concerning 2827
patients who had a single hydatid cyst of the liver (2, 3), 3)
a retrospective study of 49 recurrent liver hydatid cysts (4)
• Chemotherapy is not the ideal treatment for hyda-
tid cyst of the liver when used alone (level II of evi-
dence, grade B recommendation).
• Radical or Conservative Surgical Treatment?
1. Pericystectomy for hydatid cyst of the liver is associ-
ated with decreased postoperative infection compared
to conservative procedure such as unroofing. [OR:
0,527 95%CI (0,289 - 0,959) p: 0,036] (Level II of evi-
dence, Grade B recommendation).
2. When radical treatment is not possible, unroofing
should be associated with omentoplasty to revent post
operative infection (level I of evidence, Grade A recom-
mendation).
• The laparoscopic approach is intra operatively fea-
sible and safe (level IV of evidence, grade C recom-
mendation), laparoscopic approach is a predictive
factor of peritoneal recurrence (OR=5, 5 CI95%=1,
56  20 p = 0,008).
• Percutaneous drainage associated with albendazole
therapy is safe and efficient (level II of evidence,
grade B recommendation).
Liver hydatid cyst is still a continuing health prob-
lem in endemic area; we need more randomized tri-
als with a sound methodology.
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SY14-4
PYOGENIC LIVER ABSCESS
Nicolas Jarufe
Hospital Clınico Pontificia Universidad Catolica de
Chile, Chile
The pyogenic liver abscess (PLA) is a potentially life-
threatening disease, and has experienced significant
changes in epidemiology, management and mortality
over the past decades. The incidence ranges from 8–10
cases per 100.000 hospital admissions, being found in
0.3–1-4% of the autopsies. The spectrum of etiologies
has shifted. PLA secondary to appendicitis, diverticuli-
tis, or other intra-abdominal infective processes has
decreased due to improvements in the treatment of the
primary condition. Nowadays, biliary obstruction
(benign or malignant), stenting, or instrumentation is a
more common cause for PLA. Hematogenous spreads
from other sources, direct extension of infection into
the liver from contiguous visceral (gall bladder, stom-
ach/duodenum), abdominal trauma, percutaneous
chemoembolization or radiofrecuency of hepatic
tumors, are other examples of why PLA might develop.
However, despite these numerous possible etiologies, a
small group of patients show no identifiable cause
(cryptogenic PLA), which is reported up to 50% of all
cases. Clinical symptoms are nonspecific, and evolve
over days to several weeks, including malaise, head-
ache, anorexia, myalgia, fever or abdominal pain.
Fever, jaundice and right upper quadrant pain repre-
sent the classic “triad” in patients with hepatic abscess,
present in less than 30% of cases. If it is located adja-
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cent to the diaphragm, pleuritic pain, cough, and dysp-
nea may occur. Septic shock is more common in
patients with biliary obstruction and delayed diagnosis.
Abnormalities on physical examination may include
hepatomegaly, jaundice and right upper quadrant ten-
derness. Laboratory exams may show leukocytosis,
hypoalbuminaemia and increased C-reactive protein.
Derangements in liver function test are common, but
may be associated with sepsis rather than biliary
obstruction. Imaging studies are essential in diagnosis,
and both ultrasonography (US) and CT scan have
demonstrated good accuracy. US may show biliary
tract pathology, such as gallstones, ductal dilation, or
solid lesions and has a valuable role for early diagnosis
and percutaneous treatment. CT is more accurate than
US, especially with contrast enhancement. Peripheral
enhancement of the abscess wall is virtually diagnostic
of PLA. Moreover, CT may also show the likely cause
of PLA in approximately 70% of the cases. MRI does
not seem to have any specific advantage over CT; how-
ever, it may help to identify unsuspected liver or biliary
lesions. The principles of management include drainage
of pus, parenteral antibiotics, and treatment of the
underlying condition (if one can be found). Advances
in imaging have allowed a shift in management, from
open to percutaneous drainage. Biliary obstruction, if
present, must be relieved. Broad-spectrum antibiotics
should to be started before blood culture results are
available and should be directed at all gram-positive
and -negative aerobes and anaerobes. The microbiology
of PLA depends on the initial source of infection, but
most are polymicrobial. Escherichia coli and Klebsiella
pneumoniae are by far the most common found.
Enterococcus, Streptococcus viridans, Bacteroides and
Staphylococcus aureus have also been identified. Percu-
taneous drainage is performed under ultrasound or CT
guidance. Aspiration of the lesion should confirm the
diagnosis while obtaining pus for culture. A drain is
usually placed after the initially successful aspiration,
although its indication is still controversial. Unilocular
PLA less the 5 cm are likely to respond to percutane-
ous treatment. Large multiloculated cavities with thick
pus are prone to failure and may require surgical treat-
ment. Open surgical approach includes ultrasound
localization, division of loculations, loosening of debris
from the wall abscess, and placement of drains. Lapa-
roscopic approach has been used effectively in this set-
ting, showing less operative time and blood loss. In
specific cases liver resection is indicated, particularly in
patients with liver atrophy, multiple abscess causing
near-complete hepatic disruption, hepatolithiasis and
intrahepatic bile duct strictures. The overall mortality
of patients with PLA has decrease dramatically from
approximately 50 to around 10%, due to the advances
in diagnostic and therapeutic procedures. Risk factors
associated with mortality include septic shock, jaundice,
coagulopathy, diabetes, intraperitoneal rupture, and
malignancy. The presentation will be geared to the
modern surgical treatment of liver abscesses with mini-
mally invasive surgery.
SY15-3
LIVING DONOR LIVER
TRANSPLANTATION: TEN YEARS OF
SINGLE EGYPTIAN EXPERIENCE
Mohamed Abdel Wahab
Gastroenterology Center, Mansoura University, Egypt
Living donor liver transplantation (LDLT) is the only
hope for patients with end stage liver disease in absence
of deceased donor liver transplant program. In the past
few years, Right lobe (RL) grafts from living donors
met the increased metabolic needs of adult recipients.
This study aims to present the ten year experience with
LDLT in a tertiary high volume center in Egypt. From
May 2004 to September 2013, we performed 270 right
LDLTs. The 270 donors were selected from 1250 candi-
dates according to standard multi-step protocol. Stan-
dard and extended indications for transplantation were
considered. Patient medical records and postoperative
follow-up visits were retrospectively revised. Periopera-
tive complications were reported. After evaluating 1250
potential donors according to a multistep evaluation
protocol, 270 healthy living donors were accepted for
surgery. The main causes of donor exclusion were ABO
incompatibility (40%) and donor withdrawal (25%).
270 patients received right lobe graft. The mean age of
the recipient was 48.7 years. The most common indica-
tions for transplant were liver cirrhosis on top of HCV
induced hepatitis (65%) followed by hepatocellular
carcinoma (33%) and other indications as Budd-Chiari
syndrome and auto immune hepatitis represented 2%.
Hepatic venous outflow reconstruction was done either
without reconstruction of middle hepatic vein tributar-
ies (46%) or with reconstruction of middle hepatic vein
tributaries using either synthetic or native interposition
graft (54%). Biliary reconstruction was done by duct-
to-duct anastomoses with or without stent. The inci-
dence of major vascular complications was 3% in recip-
ients. Postoperative biliary complication rate was 35%
varying between bile leaks and biliary strictures. Patient
survival rate was 87.6% at 1 year and 79% after
5 years. Living donor liver transplantation has changed
our approach to patients with liver failure and HCC.
The donor surgery is safe and can be done with mini-
mal complications. In our transplant program, LDLT
has become the standard of care for adult patient pop-
ulation with end stage liver disease or HCC not feasible
for surgical resection. Technical improvements in the
harvesting and implantation of right grafts can provide
less morbidity and mortality for both the recipient and
the donors.
SY15-5
LDLT PROGRAM IN TURKEY
Yaman Tokat
Florence Nightingale Hospital, Turkey
Introduction: In 2012, a total of 41 centers performed a
record number of 1002 liver transplants in Turkey. %
80 of these transplants were from living donors. Con-
versely, there remains a gap of twice as many liver
transplants, which need to be performed annually.
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Method: Despite several strategies utilized to expand
the deceased donor pool, donation rate increased only
to 4.7 per million population last year. In response to
the donor shortage, living donor LT (LDLT) has pro-
gressed rapidly in Turkey.
Results: Since the start of the first successful LDLT
program in 1999, many centers have established suc-
cessful programs, with at least four centers performing
over 100 LDLTs annually.Hepatitis B was the leading
cause of liver transplantation (LT) across the country.
Among these major centers, a survey was carried out
to identify Turkish surgeon’s perspective on selection of
the LDLT donor candidates.
Conclusion: We sought to address the age limit, the
presence of mild systemic diseases, obesity, and hepatic
steatosis, as well as the technical aspects including the
anterior section drainage and utilization of grafts with
multiple portal and biliary orifices.
SY16-1
DCD DONORS. A UNIQUE SOURCE TO
SIGNIFICANTLY INCREASE ORGAN
DONATION
Juan Carlos Garcıa-Valdecasas
University of Barcelona, Spain
Donation after cardiac death (DCD) represents a
unique source to significantly increase organ donation.
Organ donations after cardiac death (DCD) are a
potential donor source that for years have caused great
controversy due to a higher rate of complications that
result in a decreased survival rate. Nevertheless, from
the time the first articles were published in which the
possibility of using these potential donors was
broached, up to the present date, use of organs from
this source has increased progressively and at present,
in this author’s view, offer the best chance for objec-
tively increasing the number of donors, in a setting in
which the lack of organs for all of the patients in need
of a liver graft is the norm.
A number of aspects should be underlined, some of
which have been noted in the article by Jay C. et al in
this issue.
Differences between donor types: Not all DCD are
equal. In our view, there are two main categories that
that are representative of two distinctly different types.
There are Maastricht category III donors, patients in
the ICU for whom the decision is made to withdraw
life-support treatment and for whom cardiac arrest is
expected. These are donors whose stay in the ICU has
been lengthy, who have typically been fed parenterally
and who have undergone some sort of aggressive treat-
ment whether it is surgery or multiple antibiotic treat-
ments. They are therefore classified as marginal or
extended criteria donors (ECD).
Then there are Maastricht category II donors who are
people who have undergone attempts at advanced car-
diopulmonary resuscitation that have proved unsuccess-
ful. These donors present a totally different situation in
which sudden death is associated with failed lifesaving
measures that put a person into a position to donate,
and in which long stays in the ICU are rare and the
risk of infection is highly unlikely. Therefore, at first
sight, these donors may be considered to be of reason-
able quality.
Differences in the types of procedures for obtaining
organs: The handling of the donor throughout the organ
retrieval process is a primary concern, as an effort must
be made to limit ischemic injuries associated with cardiac
arrest. Globally there is an absence of any type of mea-
sures insofar as category III (controlled) donors are con-
cerned. Cardiac arrest is expected and if it exceeds
30 minutes, most groups do not proceed with the
removal. In this sense the work of . . .. is important as it
shows that long before cardiac arrest happens, there is a
total lack of arterial and portal blood flow through the
liver. Only the Michigan group associates the use of an
extracorporeal membrane oxygenation machine
(ECMO) with the whole retrieval procedure in an effort
to reduce or reverse some of the injuries that happen
during this warm ischemia time. Their results show that
the use of this device improves the quality of the organs
and increases the potential donor pool by 33%
(J.Trauma, 2005;58(6):1095-101). Even so, the number
of ischemic-type biliary lesions associated with this type
of donation is high and is the most frequent cause for
graft loss and retransplantation.
As far as Maastricht category II donors are concerned,
worldwide they represent a minority of all cases and
the most important aspect in which they are involved
has been the development of procedures that allow the
body to be preserved after death has been confirmed
through the systematic use of ECMO at 37ºC (Normo-
thermic Recirculation, NR). Though small to date,
experience confirms it is possible to use these organs
safely and suggests that the incidence of ischemic-type
biliary lesions can be substantially reduced.
NECMO therefore becomes a system that when used
after cardiac arrest (both in category II and category
III donors), is able to reduce and even reverse injuries
that occur during the warm ischemia time. It eliminates
the sense of urgency, allowing the removal of organs to
be carried out safely. Some groups have suggested
using substances during this period (Fung et al), to
keep the vascular bed intact and thus avoid ischemic
injury to the biliary tract.
Difference in results: There is no doubt, as the authors
of this study confirm, that in the present circumstances
DCD is associated with lower chances of survival and
a higher rate of retransplantation. (However, as the
authors show, the survival rate for retransplants is the
same whether the initial graft came from a DCD or a
DBD.) Nonetheless, there is no question that this prac-
tice has proved to be very efficient and has allowed the
number of patients who receive transplants to increase.
That said, both types of DCD (category II and III) are
associated with very low efficiency, i.e. the whole proce-
dure for organ retrieval is often aborted due to suspi-
cions about the quality of the graft. This makes
obvious the need for improving the conditions sur-
rounding organ retrieval, in order to improve the qual-
ity of the organs harvested. This means using some sort
of device to keep the organs functioning after removal.
Perfusion machines are nothing new but until the pres-
ent time their clinical application has been negligible.
There is not yet much clinical experience. Only the Guar-
rera group has used ex situ hypothermic machine perfu-
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sion on occasion, on grafts that were a priori marginal
and which showed its usefulness. The authors (Guarrera
JV et al J.Surg Res 167:e365, 2011) suggest that hypo-
thermic machine perfusion preservation significantly
reduces proinflammatory cytokine expression when com-
pared with cold storage. Two recently published experi-
mental studies highlight the importance of ex situ
normothermic perfusion (37ºC) in improving DCD graft
quality. The Oxford group designed a perfusion machine
capable of keeping the organ (after a 60 minute cardiac
arrest) for 20 hours and achieve a survival rate of nearly
90% after transplantation. Our group has also been able
to verify the efficiency of ex situ normothermic perfusion
after 90 minutes of cardiac arrest and use of NECMO
during the procedure to obtain the liver graft. In the first
place, this experimental study underlines the importance
of using NECMO during the procedure to retrieve
organs from DCD donors, thereby confirming all the
previous data, and secondly, that the chance of organ
recovery following 4 hours of ex situ normothermic
machine perfusion (37ºC), allows achievement of a 100%
post-transplant survival rate.
To summarize: DCDs are a unique source that could
produce a significant increase in organ donation. Nev-
ertheless and according to the authors of the paper
published here, the present results could be improved.
In our opinion, mechanisms should be added during
(Normothermic Extracorporeal Machine Oxygenator)
and after the procedure to obtain the graft (Hypo or
Normothermic Machine Perfusion), which would
clearly improve two aspects: the overall efficiency of
the organ retrieval and assurance as to the quality of
the organ, by preventing ischemic complications such
as cholangiopathy.
SY16-2
USE OF MARGINAL DONORS OTHER
THAN DCD
Hoonbae Jeon
University of Illinois at Chicago, U.S.A.
Severe disparity between numbers of available donor
organs and patients on the transplant waiting list has
been a critical problem in the transplant community for
many years. For the past decade, the average age of
deceased donors has constantly increased in the United
States. Both the decreased proportion of trauma vic-
tims and the increased proportion of patients deceased
from non-traumatic cause, such as cerebrovascular dis-
ease, in the whole donor pool have contributed this
adverse trend. Especially for the last couple of years,
the total number of deceased donor has decreased. As
a result, the transplant community has been increas-
ingly forced into utilizing more organs in marginal
quality. Older donors deceased from cerebrovacular
disease have higher tendency to have medical co-mor-
bidities including, hypertension, diabetes, previous his-
tory of malignant tumor and obesity. These conditions
would lead to less than ideal quality of hepatic allograft
due to high degree of steatosis or steatohepatitis,
As a result of obesity pandemic in the western world,
excessive steatosis in livers from obese donors are more
frequently encountered. After a few well-publicized
incidents of transmission of fatal infectious disease
through solid organ transplants, screening of these dis-
eases in donors became more important. Scrutiny of
surveillance and consent process became much tighter,
as well. However, given the low incidence of disease
transmission as opposed to high risk of pre transplant
mortality, a mechanism to provide the patient with
robust information during the consent process becomes
crucial. According to many studies, carefully selected
elderly donor livers can be safely used with comparable
outcomes with ideal donor livers. There has been con-
cerns about tendency to have earlier and more aggres-
sive recurrence of hepatitis C in the recipients.
However, with advance of pharmaceutical treatment of
hepatitis C, this can be improved with preemptive treat-
ment prior to transplantation or immediately after
transplantation.
Donor livers with previous exposure to hepatitis C or
B can be also used after confirmation with biopsy in
selected resipients and prophylactic medications.
Livers from a donor with previous history of malignant
tumor can be also used in selected situations.
The easiest and the most important way to improve the
transplant outcome using donor livers in marginal
quality would be minimizing cold ischemic time.
Hypothermic ex vivo perfusion has been developed as a
better preservation method than conventional hyperter-
mic preservation especially in marginal donors. For liv-
ers with excessively high fat content, ex vivo perfusion
may offer the platform for metabolic manipulation to
“defat” the liver. This may become an important
breakthrough to increase the usage of these steatotic
donor livers.
In elderly donors, even if the quality of the liver paren-
chyma still stays acceptable, severe atherosclerotic
change of hepatic artery may preclude transplantation
of such donor liver. Donor organ shortage is persistent
and there is no dramatic solution for this yet. However,
there are a few untapped potential sources of donor
livers.
More vigilant screening of transmittable infection in
the donor and its prevention, more aggressive use of
elderly donor liver, and implementing better split algo-
rithm for good quality deceased donor liver would be
immediately available strategies to increase additional
donor livers. And better way to quantify fat content
than frozen section with HE stain seems necessary to
help decisions by the donor surgeon.
And potential recipients should be better informed
about the possibility of receiving any category of these
marginal donor organs beforehand. They should be
given opportunities to discuss the risk versus benefit
ratio of receiving such organs in their particular clinical
situations.
SY16-4
ABO-INCOMPATIBLE LIVER
TRANSPLANTATION
Hiroto Egawa
Tokyo Womens’ Medical University, Japan
Advances in ABO-blood-type-incompatible liver trans-
plantation (ABO-I LDLT) through innovations in B-
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cell desensitization aimed at preventing antibody-medi-
ated rejection (AMR) have expanded the donor pool in
Japan. Local infusion through the portal vein or hepa-
tic artery to decrease inflammatory reaction at the epi-
thelium was introduced in 2000, and rituximab
prophylaxis was introduced widely in 2004 in Japan.
This study aimed to assess the effects of rituximab pro-
phylaxis in adult ABO-I LDLT and to determine an
effective and safe rituximab regimen. We evaluated the
effects of rituximab prophylaxis on outcomes of ABO-
blood-type-incompatible living donor liver transplanta-
tion (ABO-I LDLT) in 381 adult patients in the Japa-
nese registry of ABO-I LDLT. Patients underwent dual
or triple immunosuppression with or without B-cell
desensitization therapies such as plasmapheresis, sple-
nectomy, local infusion, intravenous immunoglobulin,
and rituximab. Era before 2005, intensive care unit-
bound status, high Model for End-Stage Liver Disease
score, and absence of rituximab prophylaxis were sig-
nificant risk factors for overall survival and antibody-
mediated rejection (AMR) in the univariate analysis.
After adjustment for era effects in the multivariate
analysis, only absence of rituximab prophylaxis was a
significant risk factor for AMR, and there were no sig-
nificant risk factors for survival. Rituximab prophylaxis
significantly decreased the incidence of AMR, especially
hepatic necrosis (P < 0.001). In the rituximab group,
other B-cell desensitization therapies had no add-on
effects. Multiple or large rituximab doses significantly
increased the incidence of infection, and early adminis-
tration had no advantage. In conclusion, rituximab
prophylaxis was safe and effective in adult ABO-I
LDLT.
SY17-1
OPTIMAL PANCREATIC STENTS
(STENT VS. NO-STENT)
Jinseok Heo
Samsung Medical Center, Sungkyunkwan University,
Korea
Pancreaticoduodenectomy (PD) is the treatment of
choice for benign or malignant disease of the pancreatic
head or periampullary region. Recently, the mortality
rate has reduced to below 5 per cent in high-volume
centers. However, the morbidity rate still remains high
about 40%. 1 In particular, postoperative pancreatic
fistula (POPF) is one of the most common complica-
tion following PD and occurred in 5~40% of patients
who performed PD. Therefore, many various anasto-
motic techniques were proposed to reduce POPF,
including improvement of anastomotic technique,
reconstruction with pancreaticogastrostomy, reinforce-
ment with fibrin glue, pancreatic duct occlusion, and
use of octreotide. But, no consensus has yet been
reached on the best way of reducing the incidence of
leakage from anastomosis. Many surgeons have used a
stent across the pancreaticojejunostomy to prevent
POPFs, and a stent may be useful for diversion of pan-
creatic juice from the anastomotic site, decompression
of the remnant, and patency of the main pancreatic
duct. Some retrospective studies have reported that the
use of stent which placed in the pancreatic duct for
internal or external drainage reduced the rate of POP-
Fs. Whereas, the usefulness of non-stented pancreatico-
enteric anastomosis has been reported by other studies.
Nevertheless, draining the pancreatic fluid by inserting
an external stent in the duct demonstrated that the
pancreatic fistula following resection was dramatically
decreased from 42 to 6 %. Poon et al. investigated the
POPF following PD with this method. 127 patients
underwent elective PD between June 2000 and October
2006. 120 were included the prospective randomized
trial. All patients underwent duct-to-mucosa anastomo-
sis. The rate of POPFs in external stent group was sig-
nificantly lower than that of in non-stent group (6.7%
vs. 20%, P = 0.032). And no stenting and pancreatic
duct diameter <3 mm were significant risk factors of
POPF on multivariate analysis. So, they suggested that
external drainage of pancreatic duct with a stent
reduced the rate of POPFs following PD. Whereas,
Kuroki et at. reported that usefulness of external pan-
creatic duct stent was not observed in normal pancre-
ases.
Tani et al. investigated the rate of the POPFs according
to the stent types (internal or external). Between two
groups, the incidence of POPFs was similar (external,
20% vs internal, 26%). However, hospital stay in inter-
nal drainage groups was shorter than that of external
drainage groups. POPFs following PD is one of the
most apprehensive complications. Many surgeons tried
the various techniques to reduce the POPFs and
reported the favorable outcomes. However, due to
potential clinical and methodological heterogeneity
across the analyzed trials and conflicting results, draw-
ing a conclusion is with caution. So, in future, high-
quality randomized clinical trials with large sample
sizes are necessary for these issues.
SY17-2
PREVENTING DELAYED GASTRIC
EMPTYING
Saxon Connor
Canterbury District Health Board, New Zealand
Delayed gastric emptying is a common complication
post pancreaticoduodenectomy. A review of literature
was performed. Techniques for preventing delayed gas-
tric emptying are presented. Delayed gastric emptying
remains a common problem following pancreaticoduo-
denectomy. several technqiues for redcing its incidence
are described
SY17-3
EVIDENCE BASED STRATEGIES
TOWARDS SAFER
PANCREATODUODENECTOMY
Laureano Fernandez-Cruz
Hospital Clinic i Provincial de Barcelona, Spain
Somatostatin and its analogues are known to have an
inhibitory effect on exocrine secretion of the pancreas.
These drugs had been presumed to reduce the rate of
pancreatic fistula. Several RCT have suggested a statis-
tically significant decrease in overall postoperative com-
plications after PD with the use of perioperative
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octreotide. Other studies reported no statistically bene-
fit for the perioperative use of octreotide. Results of
meta-analysis are also conflicting. The aim of this study
is: to evaluate the effect of octreotide on pancreatic
remnant exocrine function after PD and to assess the
efficacy of this drug in the prevention of pancreas-spe-
cific complications in patients undergoing PD for pan-
creatic or periampullary lesions, excluding chronic
pancreatitis. 62 patients underwent elective pancreatico-
duodenectomy between April 2009 and December 2011.
Enrolled patients were randomized to either octreotide
or placebo. The randomization process was carried out
during the operation. Daily pancreatic juice output
measured for 10 days.
Conclusions: 1. Total pancreatic juice output was not
significantly different between the octreotide and pla-
cebo groups. 2. Significantly lower output was recorded
in patients with ADC and in patients with dilated pan-
creatic duct. 3. Morbidity and pancreatic fistula rate
were not significantly different between octreotide and
placebo groups. This study did not demonstrate an
inhibitory effect of octreotide on the exocrine pancre-
atic secretion and suggests that the routine use of octre-
otide cannot be recommended.
SY17-4
IMMUNONUTRITION FOR
PATIENTS UNDERGOING
PANCREATODUODENECTOMY
Katsunori Furukawa
Chiba University, Japan
Major surgery is a powerful stimulus for systemic
inflammatory response, which represents, if excessive
and uncontrolled, a risk factor for a state of hyperme-
tabolism with rapid consumption of endogenous energy
stores and immunological dysfunction, eventually lead-
ing to postoperative complications, including deteriora-
tion of organ function.
Substantial improvements have been made in elective
surgical care, but patients undergoing pancreatoduo-
denectomy are at increased risk of developing compli-
cations, and persistently high morbidity rates have
remained an important concern due to decreased qual-
ity of life, prolonged hospital stay, and increased treat-
ment costs.
Immunonutrition is generally defined as a combination
of eicosapentaenoic acid (EPA), arginine, and nucleo-
tides. This therapy, which aims to provide energy and
nitrogen as well as modulate inflammatory responses
and counteract postoperative impairments to the
immune system, is gaining increasing recognition. Some
randomized clinical trials have shown that patients
given immunonutrition before and after elective major
gastrointestinal surgery had a significant reduction of
both infectious complication rates and length of hospi-
tal stay compared with patients fed a standard enteral
formula. However, experimental data of its clinical
effects in patients undergoing pancreatoduodenectomy
are poorly investigated.
Now, we have performed two randomized clinical trials
in order to investigate the effects of immunonutrition
on stress responses, immune function, and infectious
complications after pancreatoduodenectomy (Clinical
trial 1)Thirty patients who underwent pancreatoduo-
denectomy were divided into three groups. Ten patients
in the perioperative group received oral supplementa-
tion enriched with eicosapentaenoic acid (EPA), argi-
nine, and RNA, for five days before surgery, prolonged
after surgery by enteral infusion. Ten patients in the
postoperative group received early postoperative enteral
infusion of the same enriched formula with no artificial
nutrition before surgery. Ten patients in the control
group received total parenteral nutrition postopera-
tively. The plasma level of IL-6 was measured as a
measure of the inflammatory response. Concanavalin A
(Con A)-stimulated lymphocyte proliferation and phy-
tohemagglutinin (PHA)-stimulated lymphocyte prolifer-
ation were determined as indices of cell-mediated
immunity. To evaluate Th1/Th2 differentiation, the
peripheral blood mononuclear cells messenger RNA
(mRNA) expression of T-bet and GATA-3 was mea-
sured by RT-PCR.
(Clinical trial 2) Fifty patients who underwent pancre-
atoduodenectomy were divided into two groups.
Patients in the immunonutrition group (n = 25)
received oral supplementation containing EPA, argi-
nine, and RNA for five days before surgery. Patients in
the control group (n = 25) received no artificial nutri-
tion and were allowed to consume regular food before
surgery. All patients received early postoperative ent-
eral infusion of a standard formula intended to provide
25 kcal/kg/day.(Clinical trial 1) In the perioperative
group, the rate of infectious complications was signifi-
cantly reduced compared with that in the other groups.
The severity of complications (Clavien-Dindo classifica-
tion) was significantly lower in the perioperative group
than in the control group. Also, the duration of sys-
temic inflammatory response syndrome was shorter in
the perioperative group than in the other groups.
Plasma IL-6 levels were lower in the perioperative
group than in the control group. Con A- or PHA-stim-
ulated lymphocyte proliferation was significantly higher
in the perioperative group than in the other groups.
mRNA expression levels of T-bet were significantly
higher in the perioperative group than in the other
groups. The ratio of T-bet/GATA-3 mRNA expression
was also significantly higher in the perioperative group
than in the other groups. In the perioperative group,
serum EPA and EPA/arachidonic acid ratios were sig-
nificantly higher than in the other groups.
(Clinical trial 2) Infectious complication rate and sever-
ity of complications (Clavien-Dindo classification) were
significantly lower in the immunonutrition group than
in the control group. The levels of plasma IL-6 were
significantly lower in the immunonutrition group than
in the control group. Con A- or PHA-stimulated lym-
phocyte proliferation was significantly higher in the im-
munonutrition group than in the control group.
mRNA expression levels of T-bet were significantly
higher in the immunonutrition group than in the con-
trol group. Serum EPA and EPA/arachidonic acid
ratios were significantly higher in the immunonutrition
group than in the control group. The levels of plasma
prostaglandin E2 were significantly lower in the immu-
nonutrition group than in the control group. Preopera-
tive and perioperative immunonutrition could protect
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against the aggravation of surgical complications, and
reduce stress responses and stress-induced immunosup-
pression after pancreatoduodenectomy. On the other
hand, postoperative immunonutrition could not per-
form these effects. The results of the two trials may
suggest that preoperative supplementation with immu-
nonutrients is necessary to demonstrate its anti-inflam-
matory and immunometabolic effects after severely
stressful surgeries.
Now, a new clinical trial in order to investigate the
additional effects of postoperative immunonutrition on
stress responses and immune function after pancreato-
duodenectomy is under recruiting.
SY18-2
EMERGING LOCOREGIONAL
THERAPY
Timothy Pawlik
Johns Hopkins University, U.S.A.
Selective internal radiation therapy (SIRT): SIRT, or
radioembolization, delivers yttrium-90 (Y-90) micro-
spheres via a catheter in the hepatic artery to treat
intra-hepatic disease. SIRT takes advantage of the fact
that the blood supply for much of the normal liver
parenchyma arrives through the portal circulation,
while tumors are preferentially fed by the arterial sys-
tem. Glass- or resin-based microspheres tagged with
Y-90 are delivered typically in a “lobar” fashion and
preferentially distribute into the tumoral and peritu-
moral vasculature, thereby delivering a high radiation
dose (>100 Gy). Because Y-90 is a beta emitter, the
effect is relatively selective and mostly affects only the
metastatic sites while sparing normal liver paren-
chyma. The two currently available Y-90 products
include SIR-spheres and TheraSphere. SIR-spheres
deliver a higher dose per treatment and are more
embolic. In contrast, the TheraSphere product delivers
a higher specific radioactivity dose per microsphere
allowing for smaller dose per treatment and are not as
embolic. Both products have been shown to be well-
tolerated. SIRT can be an effective therapy for
patients with advanced hepatocellular carcinoma, as
well as metastatic colorectal or neuroendocrine liver
disease.
SY18-4
EXTERNAL BEAM RADIOTHERAPY
FOR HEPATOCELLULAR CARCINOMA;
WHERE ARE WE NOW?
Jinsil Seong
Yonsei University College of Medicine, Korea
Radiotherapy (RT) has long been neglected due to sub-
optimal results in the treatment of hepatocellular carci-
noma (HCC) with regards to both treatment efficacy
and toxicity. However, the recent development of
treatment techniques has facilitated using RT for HCC,
which enables safe delivery of high dose radiation on
partial liver. External RT involves three-dimensional
conformal radiotherapy (3D-CRT), intensity-modulated
radiotherapy (IMRT), image-guided radiotherapy
(IGRT), stereotactic body radiotherapy (SBRT), and
particle beam therapy. Although each has its own
advantage and disadvantage, National Clinical Practice
Guidelines (NCCN) recommends 3D-CRT as a plat-
form technology and SBRT as indicated. IMRT is
more advanced technology that can make precision RT
possible with improved conformity. IGRT system is
necessary to verify precision dose delivery and also a
prerequisite in SBRT. Recently proton RT, one of par-
ticle beam RT, is being introduced. Unique characteris-
tics of dose peak at depth and low entrance dose seem
quite attractive. Several reports from Japan show
encouraging outcome. However, such advantage is fre-
quently compromised to encompass large tumor. Poor
conformity also remains to be improved as well as neu-
tron contamination and limited accessibility. Introduc-
tion of more advanced technology raises an issue of
medical cost. However, no single sophisticated technol-
ogy can open the door to disease control. Close collab-
oration among physicians with various specialties
cannot be too important.
SY19-2
CLASSIFICATION OF BILE DUCT
INJURY AND CLINICAL APPLICATION
Abe Fingerhut
Hippokration University Hospital Athens Greece,
University of Graz Austria, France
Several classifications of bile duct injury have been
developed since the still widely used Bismuth classifica-
tion. Classifications can be useful when they 1) provide
an anatomic picture of the lesion, 2) help categorize the
lesions according to complexity or severity of progno-
sis, 3) give insight to possible causes, thus leading to
preventive measures, 4)serve as guide-lines for therapy,
and 5) allow comparison of management and outcomes
between different series. A literature search and compo-
sition of a new classification. 15 different classifications
were found attesting to increasing diagnostic methods
as well as acknowledgement of insufficient descriptions,
variations of injury, and definitions. The European
Association for Endoscopic Classification “ATOM”
(standing for Anatomy, Time (Of injury), and Mechan-
sims aims to combine all the existing items in the most
widely-used classifications to date into one all-inclusive
classification, universally accepted, to allow collection
of data useful for further epidemiological and compara-
tive studies as a comprehensive classification. By collat-
ing data on all types of injury, whether culled
independently by endoscopists, radiologists and/or sur-
geons, into an user-friendly, anonymous, electronic reg-
istry (available on the EAES web site), we hope to be
able to determine the true incidence of BDI incurred
during laparoscopic cholecystectomy, and ultimately,
lead to preventive measures.
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SY19-3
CLASSIFICATION OF BILE DUCT
INJURY AND CLINICAL APPLICATION
Mariano Gimenez
Chief of HPB and Gastrointestinal Surgery, Argentina
Introduction: Biliodigestive anastomosis stenoses,
whether following surgical repair or not, are common
conditions seen by interventional radiologists. There-
fore, once a biliary injury has occurred, especially in
the case of complex lesions, repair is carried out by he-
patico-jejuno anastomosis.
The success rate of the procedure in tertiary centres
range from 85% to 95%. When the re- pair is not done
by an HPB surgeon, the results are alarmingly compro-
mised.
Strictures of biliodigestive anastomoses present with
clinical signs of repeated cholangitis, with or without
jaundice. Complementary laboratory studies report ele-
vation of alkaline phosphatase and leukocytes. Ultra-
sound identifies intrahepatic dilatation of the bile duct
in 50% of the cases and MRI can be used to identify
the stricture of the anastomosis. The presence of pneu-
mobilia and of an intestinal loop in the area may con-
found the diagnosis, especially in non-dilated bile
ducts.
Method: In many of these patients, treatment of the
cholangitis consists of antibiotic therapy and percutane-
ous drainage of the bile duct, which can also confirm
the diagnosis of a stricture. Once the infection is under
control, a percutaneous dilatation of the stricture will
be performed with a high pressure balloon, unless there
are severe construction deficiencies in the previous bili-
odigestive anastomosis. Long-term success rates with
this technique range between 45% and 71%, according
to the data series.
Recurrence rates with this technique are approximately
40% and as successive dilations are needed at around
four months, it is necessary to find other minimally
invasive treatments for these patients. When balloon
dilation is ineffective or when the patient presents with
repeated cholangitis, the treatment to follow next is still
a matter of controversy. New hepaticojejunal anasto-
mosis, liver excision or, in even selected cases, liver
transplantation may be carried out depending on the
case.
Results:
The rationale behind biodegradable stents: In the last
eight years, as another treatment option, we have been
carrying out sustained percutaneous dilatation with mul-
tiple plastic stents for 9 to 12 months at our centre and
in an unpublished series. Even though it is a treatment
which offers long-term patency results of 80%, it is
technically complex – both the placement and removal
of the catheters – and when done percutaneously,
requires one or two internal-external percutaneous
drainages for several months. Therefore, biodegradable
stents could allow sustained dilatation, without the
long-term complications of catheters or metallic stents.
The first publications referring to their possible use in
the bile duct date back to mid-2000s. Later, several ani-
mal studies confirmed their feasibility and absence of
deleterious effects in their utilisation and degradation.
This led to these stents being subsequently used in
humans. Recently, some isolated clinical cases in
benign strictures and as splints in biliodigestive anas-
tomosis have been reported. Our group has recently
published the first series and follow- up of patients with
benign biliary strictures treated with biodegradable
stents.
Conclusion:
Current models: There are various biodegradable stents
under study. The stent used by us is a biodegradable
stent manufactured from commercially available polydi-
oxanone absorbable surgical suture material. Polydiox-
anone is a semi-crystalline, biodegradable polymer
belonging to the polyester family. The stent is radiolu-
cent, with radiopaque markers at both proximal and
distal ends.
Theoretically, this biodegradable stent allows long-term
dilatation without the need for removal. It is braided
from a monofilament of specially treated polydioxa-
none, an absorbable suture and implant material in use
for over 20 years. Degradation occurs by hydrolysis.
The monofilament loses 50% of its breaking strength
after 3 weeks and is absorbed within 6 months; reduced
pH accelerates hydrolysis.
Our group has recently published the results of the first
series of patients with hepaticojejunal anastomosis ste-
nosis treated with biodegrad- able stents. The 13
patients treated showed a success rate of 84.6%, with a
follow-up of between 18 and 24 months.
During the follow-up, two patients presented symptoms
of cholangitis requiring re-drainage. In one, when new
drainage was placed, both hepatic ducts and anastomo-
sis were patent, suggesting that the stents had been
effective, but a short loop in the Y-shaped Roux used
for the hepaticojejunal anastomosis reconstruction was
observed, causing reflux of intestinal fluid to the anas-
tomosis. This condition, together with a bilateral stric-
ture, had been overlooked during the first procedure.
In these cases, cholangitis was not accompanied by
severe fluctuations of alkaline phosphatase.
In the other patient with a repeated cholangitis, re-
drainage was performed confirming the stric- ture of
the anastomosis, and a partial excision of the strictured
biliary area and a New hepaticojejunal anastomosis
were carried out. The pathology report indicated stent
inclusion in the biliary mucosa with little inflammatory
components.
The results in our series have prompted us to consider
changing the management algorithm of this condition,
and therefore, in case of strictures of biliodigestive
anastomoses without severe construction deficiencies,
the treatment option will be drainage with placement
of a biodegradable stent, thus replacing the treatment
presently used, which is balloon dilation.
At present we are investigating the use of biodegrad-
able stents in biliary tract partial stenoses without sur-
gical repair. Our preliminary experience in 4 patients is
satisfactory, but a larger number of cases are needed
with prolonged follow-up to determine the feasibility of
the method.
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SY19-4
BILE DUCT INJURY DURING
LAPAROSCOPIC CHOLECYSTECTOMY
Steven Martin Strasberg
Washington University in Saint Louis, U.S.A
Surgical treatment : Rationale of management of biliary
and vasculobiliary injuries : Management of biliary
injury requires careful preoperative preparation and
meticulous techniques of reconstruction. Key elements
in preparation are the complete diagnosis of the extent
of the injury and choosing the correct time for repair.
Early repair is desirable but certain circumstances are
unfavorable for early repair. These include vasculobilia-
ry injury, complex injuries which are difficult to diag-
nose, unstable patients, and referral during the period
of severe postoperative inflammation. Diagnosis of
complex injuries may be facilitated by retrograde injec-
tion of subhepatic drains and transhepatic U tube is
helpful in stabilizing the patients prior to surgery. The
goals of the operative procedure are to identify all
ducts and perform wide, tension free, well vascularized
anastomoses. These goals are achieved by side to side
Roux en Y hepaticojejunostomy using fine absorbable
sutures. Using these techniques excellent results may be
expected in over 95% of injuries.
SY20-3
TIPS TO AVOID OPEN CONVERSION
DURING LAPAROSCOPIOC HBP
SURGERY - FOR VESSEL INJURY/
BLEEDING DURING LIVER SURGERY
Choon Hyuck David Kwon
Samsung Medical Center, Korea
Bleeding control still remains as one of the most chal-
lenging part during laparoscopic liver resection and the
ability to control bleeding is very important for a safety
and good outcome of the patient. It also is one of the
main obstacles most laparoscopic surgeons face when
trying to expand the laparoscopic program from minor
to major liver resection. There are several core strate-
gies that can be implemented to improve control of
uneventful bleeding during parenchymal resection.
1. Pringle maneuver: Inflow control still remains as
one of the most widely used techniques used by
HPB surgeon to decrease bleeding during liver
resection. There has been several methods such
as vascular tourniquet or bulldog clamp but from
my personal experience, application of Chitwood
deBakey clamp offers the best choice. It is quick
and easy to apply and very effective. It is better
to apply the clamp from the left side rather than
right side because the hepatic artery, which needs
a higher clamping force to stop the flow, lies on
the left side of the hepatoduodenal ligament.
Inflow control provides very effective hemostasis
especially when the bleeding focus is the portal
vein and/or hepatic artery. It therefore offers
more advantage during non-anatomic liver resec-
tion where portal vein and/or hepatic artery
bleeding is often encountered compared to ana-
tomic liver resections where hepatic veins are the
usual source of bleeding.
2. Control of intraabdominal pressure (IAP) and
tidal volume: Positive intraabdominal pressure by
carbon dioxide acts as a counterbalance to bleed-
ing vessels and decreases bleeding during laparo-
scopic procedures. Despite the fear of gas
embolism, due to the high dissolution capacity of
carbon dioxide, unlike oxygen or nitrogen, it has
been shown to be relatively safe to increase IAP
during bleeding events to improve bleeding con-
trol. Excessive increase of IAP for prolonged per-
iod may result in increased blood CO2 pressure
and decrease blood circulation resulting acidosis
and drop of BP. Since bleeding from hepatic
veins is a result of difference of pressure between
CVP and IAP, the balance between CVP and
IAP pressure is important and should always be
considered so that both bleeding and CO2 embo-
lism can be maintained to minimum. Therefore
the application of increased IAP should be done
selectively with care. I usually perform the whole
operation under 11 mmHg pressure and during a
bleeding event, I increase the IAP stepwise (11 a
15 a 18 a 20 mmHg) until the balance between
CVP and IAP is achieved for minimal bleeding
and gas embolism. Additionally, by lowering the
tidal volume, CVP may further be reduced with-
out additional CO2 embolism, providing another
safe and quick method to reduce bleeding from
hepatic veins.
3. Low CVP: Low CVP anesthesia has been one of
the most important skills provided by the
anestheologist during open liver resection and
still remains as important during laparoscopic
liver resection. The surgeon should always main-
tain close relationship with the anestheologist
and share important information during the
whole surgical procedure.
1. Controlling unexpected bleedings: Here are some
important surgical tips that may be applied dur-
ing unexpected bleeding.
1. Grasp or compress the bleeder as soon as pos-
sible: Before other procedures necessary for
bleeding control are being prepared such as
preparing for sutures, it is important to grasp
and/or compress the bleeder as soon as possi-
ble. It not only decreases the total amount of
blood loss during bleeding control, but also
provides a good surgical field necessary for
precise bleeding control.
2. Compression using gauze and/or hemostatic
agent: Because the hepatic vein is a low pres-
sure system, simple compression using gauze
and/or hemostatic agents often stops or
decreases the bleeding amount.
3. Bipolar electrocautery: Because the cauteriza-
tion of a bipolar system is more superficial
and wide, bipolar electrocautery is much more
effective and safe to control bleeding from
hepatic and portal vein compared to monopo-
lar electrocautery which can make “a hole” on
the vein. A wide based fenestrated bipolar tip
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along with sufficient saline provides the best
cauterization.
The following stepwise procedures are usually done
during bleeding from major hepatic veins and/or IVC:
Grasp and/or compress the bleeding point a Identify
the exact bleeding point a Apply bipolar electrocauter-
ization a Increase IAP and/or decrease tidal volume a
Apply pringle maneuver whenever necessary a Get ade-
quate surgical vision a Suture using prolene 5-0 and/or
4-0.
SY21-1
REPEAT RESECTION FOR
INTRAHEPATIC AND EXTRAHEPATIC
RECURRENCE
Masakazu Yamamoto
Tokyo Women’s Medical University, Japan
HCC recurrences are big problems after curative hepa-
tectomy. Surgical treatments for HCC recurrences were
studied. 761 patients underwent curative hepatectomy
in TWMU from 2000 to 2011.The 5-year cumulative
OS and DFS are 66 % and 30%, respectively. In the
series, 422 patients (55%) have recurrence after surgery.
Liver was the most common recurrent site, and intrahe-
patic and extrahepatic recurrent rates were 89% and
11%, respectively. The extrahepatic recurrent sites were
lung, lymph nodes, bone, brain and adrenal glands. In
patients with intrahepatic recurrence, 74% were found
as hepatic recurrence which supposed to candidates for
aggressive treatments such as RFA and LR (hepatec-
tomy) in our surveillance system. The 5-year OS was
significantly better in LR and RFA than TACE for the
treatment of single intrahepatic recurrence less than
3 cm in diameter. OS and DFS found no different
among the treatment modalities for multiple intrahe-
patic recurrences. OS was better in selected surgical
patients than other treatments for extrahepatic recur-
rences. Curative management of recurrence achieved
long-term survival, especially repeat resection should be
considered for single intrahepatic recurrence, further-
more for extrahepatic recurrences when it could be
resectable.
SY21-2
TREATMENT OF PULMONARY
METASTASIS
Shin Hwang
Asan Medical Center, Ulsan University, Korea
Liver transplantation (LT) has become an established
treatment modality for patients with hepatocellular car-
cinoma (HCC). Although the criteria for LT in patients
with HCC have been expanded, there are as yet no reli-
able methods to treat posttransplant HCC recurrence
effectively. One important characteristic of posttrans-
plant HCC recurrence is the high incidence of extrahe-
patic metastases, with pulmonary metastasis (PM)
frequently observed in patients with or without intrahe-
patic metastases. Pulmonary metastasectomy (PMT)
has become the standard therapy for various metastatic
malignancies to the lungs. Because PM-HCC often
involves multiple sites in the lungs, resection has not
become a standard practice. Although resection of PM-
HCC has been found to enhance disease control and
prolong survival in non-LT patients, the clinical char-
acteristics of LT recipients with PM-HCC may differ
from those of non-LT patients. The institutional experi-
ence with resection of PM-HCC in LT recipients is
described here. This study intended to assess the effect
of resection of PM of HCC after LT. Of 587 adult LT
recipients diagnosed with HCC, 43 had PM-HCC. We
retrospectively compared outcomes in 23 patients who
underwent PMT and 20 who did not. PMT was pre-
cluded in 10 patients in the non-PMT group by multi-
ple (usually ≥ 5) lung nodules, in 9 by lung nodules
with concurrent or residual extrapulmonary metastasis,
and in 1 by co-morbidity. Of the 23 patients in the
PMT group, 14 underwent a single session of PMT, 7
underwent 2 sessions each and 2 underwent 3 sessions
each, for a total of 34 sessions. There were no surgery-
related deaths or complications. After first PMT, 41
nodules, each 0.2–2.5 cm in diameter, were observed, 1-
5 nodules per patient. Every available treatment was
provided to patients with post-PMT recurrence and
those in the non-PMT group to control pulmonary and
extrapulmonary metastases. Patient survival rates
before PM diagnosis did not differ between the two
groups. However, 2-year post-PM survival rate was sig-
nificantly greater in the PMT group (30.6% vs. 0%),
resulting in a significantly greater overall 5-year sur-
vival rate (44.7% vs. 12.8%). Univariate analysis
showed no risk factor significantly associated with
patient survival after PMT. In conclusion, resectable
PM-HCC can be detected early by frequent assays of
serologic tumor markers combined with chest CT
scans. PMT should be performed for resectable PM-
HCC because it may provide a chance of long-term
survival in a considerable proportion of patients.
SY21-3
TREATMENT OF EXTRAHEPATIC
INTRA-ABDOMINAL METASTASIS
David L Morris
University of New South Wales, Australia
Hepatocellular Carcinoma - Treatment of Extra Hepa-
tic Intra-abdominal Metastases
Morris DL and Chua TC
Extrahepatic intra abdominal metastasis of HCC is
regarded by most as untreatable. This paper offers
data to support a contrary view.
Lymph node metastasis in HCC when treated by lym-
phadenectomy was associated with a 14 month median
survival in 49 patients (Sun 2007) and adrenal metasta-
sis with 21 months median survival (Park 2007) and
5 year survival in 25% (Momoi 2002)
Peritoneal metastasis is our particular interest and we
have seen survival of up to 37 months after peritonec-
tomy/HIPEC for HCC.
New drugs for HCC are likely to alter our whole
approach to metastasis and exciting invitro and invivo
data of a novel anti tumor agents including our drug
Monepantel will be presented.
Clinical Study
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Described
New drugs for HCC are likely to alter our whole
approach to metastasis
SY21-4
NON-SURGICAL MULTIDISCIPLINARY
APPROACH FOR RECURRENT HCC
Kang Mo Kim
Asan Medical Center, Ulsan University, Korea
Recurrent hepatocellular carcinoma (HCC) after cura-
tive resection is the main obstacle against long term
survival of HCC patients. Recurrent HCC occurs
mainly in the remaining liver and all the recurrence
does not necessarily mean intrahepatic or distant
metastasis. About half of the recurrence after curative
resection is intrahepatic de novo HCC and typically
develops later than 2 years after initial resection. If
time to recurrence is less than 2 years, this recurrence
is more likely intrahepatic metastasis and has poor
prognosis than de novo recurrence. Because of different
recurrence mechanism, recurrent HCC is inherently het-
erogeneous disease entity and adequate treatment strat-
egy has to be individualized according to tumor and
host factors, such as tumor number, size, location, and
patients’ condition including liver function and even
personal preference. Considering cause of death of over
90% of HCC patients is intrahepatic reason such as
hepatic failure, meticulous control of intrahepatic HCC
could have survival benefit even in recurrent HCC. In
patients with early local recurrence or late de novo
HCC, local treatments such as re-resection, local abla-
tion, transarterial chemoembolization (TACE) seems to
have survival benefit although there has been no pro-
spective validation in recurrence setting. Remaining
liver function and HCC location and multiplicity usu-
ally determine which local treatment will be the initial
treatment in clinical practices. Considering incidence of
treatments in the whole course of HCC treatment,
TACE is the mainstay treatment among local treatment
options. If recurrent HCC fails to respond to local
treatments or there is clinically significant distant
metastasis, systemic targeted therapy, sorafenib, is indi-
cated with limited efficacy. More recently, radiation
therapy (RT) is becoming more and more popular as a
palliative therapy of HCC especially in Asian countries.
For the best outcome in patients with recurrent HCC,
we have to approach in an individualized strategy
because of the heterogeneity of disease. Proper local
treatment has to be applied to control intrahepatic
HCC in all the recurrent patients if possible. Definitely
we have to consider sorafenib in patients who fail in
local treatments or have distant metastasis. It is
expected that multidisciplinary approach according to
individual patients’ condition and combination therapy
of local treatments including RT, sorafenib and even
novel therapies could maximize survival benefit in
recurrent HCC patients.
SY22-1
STAGING OF NON-FUNCTIONING
NEUROENDOCRINE TUMORS OF THE
PANCREAS
Andrea Frilling
Imperial College London, United Kingdom
Introduction: Accurate staging is pivotal for effective
treatment, follow-up and prediction of prognosis in
patients with pancreatic neuroendocrine tumors
(PNET). Non-functioning PNET are frequently large
in size and of cystic appearance. Approximately 30%
of cases present with metastases at the time of initial
diagnosis.
Method: Standard cross-sectional imaging modalities
used in diagnosis, staging and follow-up of patients
with PNET include ultrasonography (US) either con-
ventional or as a contrast enhanced technique (CEUS),
computed tomography (CT) and magnetic resonance
imaging (MRI). Somatostatin receptor based imaging
performed in PET/CT technique utilising 68 Ga-DOTA
agents is the mainstay single-staging method for extra-
hepatic disease.
Results: Compared to US, CEUS detects significantly
more hepatic metastases (LM). The current sensitivities
and specificities for PNET detection with CT and MRI
range from 64%-82% and 74%-100%, respectively.
Multiphase helical CT with a multi-row detector CT
scanner is more efficacious in detection of LM than
conventional single portal venous phase CT. Diffusion-
weighted MRI is the most sensitive MRI technique at
present. It depicts more and smaller LM than
CT.68 Ga DOTA- PET/CT been shown to have an
app. 30% higher sensitivity in assessment of metastatic
low grade PNET when compared to standard imaging.
The technology is particularly helpful for detection of
bone metastases and lymph node metastases. Interme-
diate and high grade PNET express low density of
somatostatin receptors and are therefore better detect-
able on 18FDG PET/CT. Endoscopic ultrasound
(EUS) has the potential to localize PNET (82% sensi-
tivity and 92% specificity) and provide tissue diagno-
sis. It is well suited to identification of previously
unlocalised small lesions in the pancreatic head and
body and for detection and tissue confirmation of peri-
pancreatic lymph nodes.
Conclusion: More than 50% of neuroendocrine LM
will be understaged by present imaging when compared
to histopathology results of resected liver specimens.
SY22-2
RECENT CONCEPTS NON-
FUNCTIONING PANCREATIC
NEUROENDOCRINE TUMOR (PNET)
Palepu Jagannath
Lilavati Hospital & Research Centre, India
Neuroendocrine tumors are now called neuroendocrine
neoplasia (NEN) according to WHO classification 2010
of GEP NETs. Treatment depends on histopathologi-
cal grading (G1,G2, G3), location of tumors, functional
status, ,nodal involvement and metastasis. Histopatho-
logical grade is an important determinant in planning
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management. Well differentiated G1 and G2 NENs are
classically treated by surgery Resection is planned on
basis of size, confinement to pancreas and adjacent
organ or large vessel invasion, relationship to pancre-
atic duct. Our series In our series of 218 patients as
part of Asia Pacific NET registry, pancreas was most
common site (45%). Well differentiated neuroendocrine
carcinomas (G2) (31.68%) and well differentiated neu-
roendocrine tumors (G1) (29.7%) were almost equal.
Surgery was performed in 163 patients, both for pri-
mary and liver mets. Non-functioning tumours were
more common (86%). Insulinoma was the most com-
mon functioning tumour. Rare hypoglymia producing
tumour like proinsulinoma was diagnosed. Functioning
tumours: Insulinoma and Glucoganoma are the most
common functional pancreatic NENs that are usually
small and tumor localisation if often a challenge. Con-
trast enhanced MRI and endoscopic ultrasound are
useful for localising small functional tumors. Small and
localised functioning NENs can be treated with enucle-
ation and pancreas preserving resections. MRCP is
used to determine relation ship to pancreatic duct
(PD). Median pancreatectomy is done for tumours
around neck close to the pancreatic duct. The proxi-
mal stump is stapled and distal cut end is anastomosed
by duct to mucosal anastomosis to jejunum. For
tumours of body close to PD spleen preserving distal
pancreatectomy is done depending on location. Laparo-
scopic approach is preferred.Nonfunctioning tumours: In
contrast non-functioning pancreatic NENs present as
mass lesions diagnosed incidentally or with pressure
symptoms. DOTATOC PET scan is a useful imaging
modality for NENs. Usually large non-functioning
tumors need radical resections such as pancreatoduo-
denectomy or a spleen preserving distal pancreatectomy
depending on tumor location. Resection of adjacent
organs like colon or stomach is justified to achieve R0
resection.
Pancreatic NENs with liver metastasis: Liver metasta-
ses were found in 92 patients. These need a tailored
approach. A resection of the primary and debulking of
metastasis should be strongly considered. Synchronous
or staged resection to debulk the disease is necessary.
The functioning status can be controlled preoperatively
by Octreoitide LAR, RFA or trans arterial chemo em-
bolisation (TACE). These are also options to treat
residual liver metastasis. Non surgical treatments: G1
and G2 tumors can also treated by peptide receptor
tagged radiotherapy (PRRT) using lutetium 177 if they
have positive receptors on Somatostatin Scintigraphy.
M-TOR inhibitor - Afinitor is used for nonresectable
or metastatic pancreatic NETs while poorly differenti-
ated G3 tumors are treated with chemotherapy. Pancre-
atic NETS are commonly non-functioning and are
diagnosed with metastatic disease. Aggressive debulking
surgery for primary and metastases is recommended.
Grade is an important prognostic factor.
SY24-1
MANAGEMENT OF GALL BLADDER
CANCERS IN THE ERA OF MINIMAL
ACCESS SURGERY (INDIAN
APPROACH)
Prasad Wagle
Lilavati Hospital and Research Centre, India
Gallbladder cancer has a varied incidence in India,
being highest in North India where it is the commonest
gastrointestinal malignancy in women.
Approximately 60% – 90% of Gallbladder cancers are
associated with gallstones.
Gallbladders with stones & polyps> 1 cm, stones >
3 cm & porcelain gallbladders carry the highest risk.
Heavy metals have also been implicated as causative
agents. The impact of laparoscopic cholecystectomy for
patients with asymptomatic gallstones from high ende-
mic zones needs to be further studied.
Issues discussed will be as follows:
• Suspected GB cancer pre op : Lap or open ?
• Unsuspected GB cancer detected on Histopathology
what next ?
• Port site recurrence local or distant mets ?
• Delayed recurrence in early GB cancer
• Does lap cholecystectomy have a negative impact on
survival in unsuspected GB cancers ?
• Advanced gallbladder cancer
Laparoscopic cholecystectomy is the gold standard for
treating gallstones.
However if cancer is suspected preoperatively cholecys-
tectomy is best done open.
On incidental detection of cancer & appropriate patho-
logic staging, if invasion of muscle coat or beyond is
present a revision radical surgery entailing removal of
gallbladder bed/seg4a&5 along with lymph nodes in the
hepatoduodenal ligament is required.
Rt trisectionectomy is possible in a small subset in
patients with T4 disease & no distant spread. India is
one of the high incidence zone for Gallbladder cancers,
wore so in the northern belt.
Majority present in the advanced stage with a remote
chance of cure. The best survivors are the ones detected
incidentally & the ones wherein a revision surgery is
offered.
SY24-2
AGRESSIVE SURGICAL TRAETMENT
FOR HILAR CHOLANGIOCARCINOMA
(UKRAINE APPROACH)
Oleg Kotenko
National Institute of Surgery and Transplantology, Kiev,
Ukraine
Vascular invasion is a main cause irresectability of peri-
hilar cholangiocarcinoma. However innovative surgical
technologies allow resecting involved portal vein with
acceptable mortality. Invasion of the hepatic artery,
often combined with invasion of portal vein, still
remains the most serious obstacle in resection of this
disease. The aim of our study was to asses results of
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surgical treatment of perichillar cholangiocarcinoma
with portal vein and hepatic artery invasion.
We studied results of surgical treatment 136 patients
with Klatskin tumor period 2003 -2012 y. T2a TNM
stage had 1,6% patients, T2b – 2,2% patients, T3
TNM stage had 38% patients, and most patients had
T4 stage TNM (58% patients). Bismuth type B2 had 1
patient, B2a – 41 patients, B3b – 36 patients, B 4 – 58
patients. For patients with small remnant liver volume
less than 40 % we did preoperative PV embolization of
a resected part of the liver. RPV embolization we did
in 58,3% right hemyhepatectomy, RPVE with Sg4
embolization – for 62,52 % right trisectionectomy,
LPVE and RAPVE for 68,5% left trisectionectomy. PV
resection was made 71 (52,2%) patients, Right HA
resection and reconstruction we did for 8 cases, com-
bined PV and HA resection and reconstruction we did
for 8 –cases, hepatopancreatoduodenectomy – for 7
patients. In all cases we made extended lymphadenecto-
my. Mortality was 8,1 % (11 patients). 3 and 5 years
reccurence-free survival was higher in group with R0
resection 33,3% and 20,8% respectively, for patients
with vascular reconstruction – 14,6 and 6,3 %, and was
smaller for group with R1 resection. 3 and 5 years sur-
vival was higher in group with R0 resection 58,3% and
33,3% respectively, for patients with vascular recon-
struction – 31,5 and 18,8 %, and was smaller for group
with R1 resection – 22,2% и 11,1%. Aggressive surgical
treatment for cholangiocarcinoma the confluence of bile
duct with hepatic artery and portal vein resection can
be performed safely with acceptable lethality and long
term survival rate.
SY24-3
A NOVEL INVAGINATED ROUX-EN-Y
HEPATICOJEJUNOSTOMY AFTER
MESOHEPATECTOMY FOR HILAR
CHOLANGIOCARCINOMA OF
BISMUTH-CORLETTE TYPE III
Xiao-Ping Chen
Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology, China
Major liver resection for Bismuth-Corlette type III hilar
cholangiocarcinoma (HC) is reportedly associated with
high morbidity and mortality. Limited liver resection
such as mesohepatectomy with resection of tumor-
involved bile ducts could be a way to improve surgical
outcomes of HC. However, biliary tract reconstruction
after mesohepatectomy poses a great technical chal-
lenge. We established a new invaginated hepaticojejun-
ostomy (IHJ) for biliary tract reconstruction especially
for multiple hepatic duct openings. This study aims to
evaluate the safety and effectiveness of IHJ. A total of
156 patients with Bismuth-Corlette type III HC under-
went radical resection from 2001 to 2012. 113 patients
underwent mesohepatectomy, and 43 underwent hemi-
hepatectomy or extended hemi-heatectomy. IHJ was
adopted in 109 patients, and traditional hepaticojejun-
ostomy (THJ) in 47 patients. Short-term surgical out-
comes between two groups were compared. 48 pigs
were equally divided into two groups. One underwent
IHJ, and another group underwent THJ. Healing pro-
cess of IHJ was pathologically studied. The clinical
data of the patients undergoing IHJ and THJ were
shown in Table 1. No death within 30 postoperative
days in the both groups. The postoperative morbidity
in IHJ group is significantly lower than that in THJ
group. Animal experiment revealed that the cross sec-
tion connecting to the enteric cavity was gradually cov-
ered by regenerated enterocytes, leaving a small part
covered by regenerated biliary epithelial cells. IHJ
after mesohepatectomy for Bismuth-Corlette type III
HC is a simple, effective procedure with significant less
morbidity. Animal study confirmed that IHJ was excel-
lently healed without any problem.
SY24-4
RUSSIAN APPROACH TO HILAR
CHOLANGIOCARCINOMA
Vladimir Vishnevsky
Vishnevsky Institute of surgery, Russia
Hilar cholangiocarcinoma is the most common biliary
tract malignancy. The aim of the study was analysis of
long-term results after R0 and R1 resections in patients
with hilar cholangiocarcinoma. Proximal bile duct
resections with or without major liver resections were
performed in 132 patients. Ninety five percent of iso-
lated bile duct resections were performed before 2003.
Long-term results of bile duct resections with or with-
out major liver resections were assessed. One hundred
and four patients (79%) were followed up from 0,5 till
12,5 years. Hospital mortality was included in calcula-
tion of survival. Overall 5-year survival after R0 and
R1 resections was 23%. There was no significant differ-
ence in survival before and after 2003 (19% and 37%
respectively, p > 0,05). Three factors discovered inde-
pendent significant impact on survival in multivariate
analysis: 1) age > 60; 2) R0 vs R1; 3) stage TNM, 2010
(I, II vs III, IV). There was no difference in survival
after bile duct resections with and without major liver
resections. Five-year survival was 22% and 34%
respectively. Major liver resections were applied more
frequently in patients with III, IV stages TNM in com-
parison with minor liver resections and isolated bile
duct resections (73% and 49% respectively). Five-year
survival after bile duct resections with and without
major liver resections was 75% and 46% respectively in
patients of <60 years old age with I, II stages TNM.
Caudate lobe resection combined with major liver
resection was performed in 44% of patients. Five-year
survival of patients with R0 resections after caudate
lobectomy was 60%, without caudate lobectomy –
42%. The crucial point in improvement of survival in
patients with hilar cholangiocarcinoma is R0 resection.
The most restrictive factor for survival was III, IV
stage of disease according TNM classification. Aggres-
sive surgery is justified if R0 resection is achievable.
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